

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/20909> holds various files of this Leiden University dissertation.

Author: Bruggink, Cornelis

Title: Characterization of oligosaccharides with capillary high performance anion exchange chromatography hyphenated to pulsed amperometric detection and ion trap mass spectrometry

Issue Date: 2013-05-29

5

ANALYSIS OF URINARY OLIGOSACCHARIDES
IN LYSOSOMAL STORAGE DISORDERS
BY CAPILLARY HIGH-PERFORMANCE
ANION-EXCHANGE CHROMATOGRAPHY-
MASS SPECTROMETRY

5.1 ABSTRACT

Many lysosomal storage diseases are characterized by an increased urinary excretion of glycoconjugates and oligosaccharides that are characteristic for the underlying enzymatic defect. Here, we have used capillary high-performance anion-exchange chromatography (HPAEC) hyphenated to mass spectrometry to analyze free oligosaccharides from urine samples of patients suffering from the lysosomal storage disorders fucosidosis, α -mannosidosis, G_{M1} -gangliosidosis, G_{M2} -gangliosidosis, and sialidosis. Glycan fingerprints were registered, and the patterns of accumulated oligosaccharides were found to reflect the specific blockages of the catabolic pathway. Our analytical approach allowed structural analysis of the excreted oligosaccharides and revealed several previously unpublished oligosaccharides. In conclusion, using online coupling of HPAEC with mass spectrometric detection, our study provides characteristic urinary oligosaccharide fingerprints with diagnostic potential for lysosomal storage disorders.

Cees Bruggink^{1,2}, Ben J. H. M. Poorthuis³, André M. Deelder¹, Manfred Wuhrer¹

¹ Biomolecular Mass Spectrometry Unit, Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.

² Thermo Fisher Scientific, Amsterdam, The Netherlands.

³ Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands.

Analytical and Bioanalytical Chemistry (2012) 403; 1671–1683.

5.2 INTRODUCTION

Fucosidosis, α -mannosidosis, G_{M1} -gangliosidosis, G_{M2} -gangliosidosis, and sialidosis are autosomal recessive lysosomal storage diseases (LSD). These LSDs are the result of defects of one or more enzymes or cofactors involved in the catabolism of glycoconjugates that takes place in the lysosome. Fucosidosis is caused by a deficient lysosomal α -L-fucosidase (EC 3.2.1.51) and results in secretion of fucosyl-oligosaccharides [1,2]. Deficient lysosomal α -D-mannosidase (EC 3.2.1.24) causes α -mannosidosis and excessive urinary excretion of oligomannosidic glycans [3-5]. Sialidosis is caused by deficient acid exo- α -sialidase (EC 3.2.1.18) [6]. The urinary excretion of sialyloligosaccharides is similar to that found in galactosialidosis [1,7]. G_{M1} -gangliosidosis is a neurosomatic disease due to the deficient activity of β -galactosidase (EC 3.2.1.23) [8,9]. In addition to the storage of G_{M1} -gangliosides, glycoconjugates with β -galactose at the non-reducing end are increased in patients' urine.

G_{M2} -gangliosidosis is a group of three disorders (1) Tay-Sachs disease, (2) Sandhoff disease, and (3) AB variant. For all variants of G_{M2} -gangliosidosis, the major neural storage compound is ganglioside G_{M2} [10-12]. Only in Sandhoff disease oligosaccharides derived from glycoproteins accumulate due to the deficiency of β -hexosaminidase A in addition to the (functional) deficiency of β -hexosaminidase B [13]. Blockage of the *N*-glycan catabolism results in accumulation of oligosaccharides carrying a single *N*-acetylglucosamine residue at the non-reducing end in tissues and urine of Sandhoff disease patients [14-16]. The current study includes the analysis of urine samples of patients suffering from Sandhoff disease.

Biochemical screening of these LSDs is usually performed using thin-layer chromatography (TLC) [17-19], since TLC is relatively easy to perform and does not require expensive equipment. However, interpretation of a TLC pattern of excreted oligosaccharides requires much experience in pattern recognition. On the other hand, liquid chromatography combined with UV [20] or fluorescence [21] detection is easier to reproduce and to interpret [22,23].

Hyphenation of liquid chromatography with mass spectrometry allows the detailed characterization of oligosaccharides [24]. We have previously described a capillary high-performance anion-exchange chromatograph (HPAEC) setup with combined integrated pulsed amperometric detection (IPAD) and ion-trap mass spectrometric detection which was used to characterize oligosaccharides from urine of G_{M1} -gangliosidosis [25] and galactosialidosis [26] patients. This combination of chromatography IPAD and mass spectrometric detection allows detailed glycan analysis and characterization, when compared with TLC, HPLC, or HPAEC-IPAD without mass spectrometry (MS). Using this analytical setup we report on the analysis of oligosaccharides in urine samples of fucosidosis, α -mannosidosis, G_{M1} -gangliosidosis, G_{M2} -gangliosidosis, and sialidosis patients. The results provided in glycan fingerprints that are found to be characteristic for the individual diseases and reflect the specific enzymatic defects.

5.3 MATERIALS AND METHODS

5.3.1 Materials

Analytical-reagent-grade sodium hydroxide (50% w/w), sodium acetate, sulfuric acid, and sodium chloride were obtained from J.T. Baker (Deventer, The Netherlands). Acetonitrile was

from Biosolve (Valkenswaard, The Netherlands). All solutions were prepared using water from a Milli-Q synthesis system from Millipore BV (Amsterdam, The Netherlands). Details on urine samples are given in Table 5-1.

5.3.2 Sample preparation

Oligosaccharides of the samples were isolated with graphitized carbon solid-phase extraction, as described previously [27]. A 200- μ L sample was diluted with 1800 μ L water and loaded on a CarbograpH SPE (210142) from Alltech Associates Inc. (Deerfield, IL). The cartridge was washed with 6 mL of demineralized water. The oligosaccharides were eluted from the column with 3 mL of 25% acetonitrile containing 0.05% trifluoroacetic acid. The eluate was evaporated under a nitrogen stream at room temperature until the volume was decreased by 50%. The remaining solution was lyophilized and reconstituted with 200 μ L water.

5.3.3 Capillary HPAEC

The capillary chromatographic system consists of a modified Dionex BioLC system from Thermo Fisher Scientific (Sunnyvale, CA, USA) comprising a microbore GP40 gradient pump, a Famos micro-autosampler with a full PEEK (polyether ether ketone) injector equipped with a 1 μ L loop and an ED40 electrochemical detector. BioLC control, data acquisition from the ED40 detector, and signal integration was supported by Dionex Chromeleon software (Thermo Fisher Scientific). This modified system has been described in detail before [25]. A prototype capillary column (250 $\times$ 0.4 mm I.D.) packed with CarboPac PA200 resin was manufactured by Thermo Fisher Scientific. The GP40 eluent flow was split by a homemade PEEK splitter to 10 μ L $\cdot$ min⁻¹. The pump was provided with the following eluents: eluent A, water; eluent B, 500 mM sodium hydroxide; eluent C, 500 mM sodium acetate. All separations were performed at room temperature. The following ternary gradient was used for separating oligosaccharides of fucosidosis, G_{M2}-gangliosidosis, and sialidosis: 76% A + 24% B (-20 to -14 min) isocratic sodium hydroxide column wash; 88% A + 12% B (-14 to 0 min) isocratic equilibration of the column; a linear sodium acetate gradient (0–55 min) to 25.5% A + 12% B + 62.5% C was used for the separation. For separating oligosaccharides of α -mannosidosis and G_{M1}-gangliosidosis, the following ternary gradient was used: 76% A + 24% B (-20 to -14 min) isocratic sodium hydroxide column wash; 88% A + 12% B (-14 to 0 min) isocratic equilibration of the column; linear sodium hydroxide gradient (0 to 9.1 min) to 60% A + 40% B; 60% A + 40% B (9.1 to 12.5 min) isocratic;

Table 5-1. Information about the urine samples. The age at the time point of sample gathering is given.

Sample code	Disorder	Sex	Age (years)	Creatinine (mmol/L)
U1	Fucosidosis	M	18	2.22
U2	G _{M1} -gangliosidosis	F	0.42	1.04
U3	G _{M2} -gangliosidosis	M	0.75	5.37
U4	G _{M2} -gangliosidosis	M	0.58	1.04
U5	α -Mannosidosis	M	22	18.86
U6	α -Mannosidosis	F	7	8.46
U7	α -Mannosidosis	M	20	14.52
U8	Sialidosis	F	Unknown	Not determined

linear gradient (12.5 to 21.6 min) to 85.2% A + 12% B + 2.8% C; linear sodium acetate gradient (21.6 to 104 min) to 60.5% A + 12% B + 27.5% C. Samples were injected at time 0.0 min.

The ED40 detector applies the following waveform to the electrochemical cell: $E_1 = 0.1$ V ($t_d = 0.00$ – 0.20 s, $t_1 = 0.20$ – 0.40 s), $E_2 = -2.0$ V ($t_2 = 0.41$ – 0.42 s), $E_3 = 0.6$ V ($t_3 = 0.43$ s), $E_4 = -0.1$ V ($t_4 = 0.44$ – 0.50 s) versus an Ag/AgCl reference electrode [28]. A 1 mm gold work electrode and a 25 μ m gasket were installed.

5.3.4 Mass spectrometry

Coupled to the chromatographic system was an Esquire 3000 ion trap mass spectrometer from Bruker Daltonics (Bremen, Germany), equipped with an electrospray ionization source. To convert the HPAEC eluate into an ESI compatible solution, an in-line prototype desalter (Thermo Fisher Scientific) was used which was continuously regenerated with 12.5 mM sulfuric acid with a flow rate of 0.8 ml/min [25]. A modified microbore AGP-1 (Thermo Fisher Scientific) was used as an auxiliary pump: to obtain efficient ionization of the eluted carbohydrates in the positive mode, 0.6 mM NaCl in 50% acetonitrile was pumped into the eluent flow via a MicroTEE (P-775 Upchurch Scientific, Oak Harbor, WA, USA) at a flow rate of 4.6 μ L·min⁻¹. The mixture was directed to the electrospray ionization interface of the Esquire 3000 used in the positive mode. The MS was operated at the following conditions: dry temperature 325 °C, nebulizer 103 kPa, dry gas 7 l·min⁻¹, capillary voltage -3,500V, target mass m/z 850, scan speed 13,000 m/z / s in MS, scan range 150 – 2,000 m/z , ICC target 50,000 or maximum accumulation time 50 ms, and MS/MS mode. For tandem MS automatic selection of three precursors was applied with absolute threshold 10000 or 5% relative, smart fragmentation amplification 30%–100% and 1.40 V, fragmentation time 40 ms.

5.3.5 System suitability check

To check the correct functioning of the complete instrumental setup, every sequence started with analyzing a 50 nmol·ml⁻¹ lactose solution with 60 mM NaOH as eluent. The resulting MS chromatogram should pass the following criteria: The retention time 7.5 min $\pm$ 15%; in the total ion current chromatogram, the baseline level intensity should be ≤ 4.5 e6, the noise intensity ≤ 7.5 e5; for the extracted ion chromatogram (m/z 365 $\pm$ 0.5), the peak height intensity ≥ 4.5 e6 with a peak width at half height of ≤ 5 s.

5.3.6 Data analysis

MS as well as MS/MS spectra were manually interpreted using DataAnalysis (version 3.3, Bruker Daltonics). The extracted ion chromatograms (EIC) were used in order to determine the peak area of oligosaccharides present in the MS spectra. Signals of all detected charge states and isomers corresponding to the same compound were added up. Peak areas were normalized to the sum of all glycan peak areas of one sample.

5.4 RESULTS

Free oligosaccharides from eight urine samples of patients suffering from various LSDs including fucosidosis, α -mannosidosis, G_{M1} -gangliosidosis, G_{M2} -gangliosidosis, and sialidosis

(Table 5-1) were analyzed by HPAEC-IPAD-MS to investigate disease-related, excreted degradation products. A total of 54 glycans were analyzed in these urine samples as sodium adducts using positive ion mode mass spectrometry. The set of 54 glycans was established by manual assignment of glycan species from all HPAEC-MS(/MS) data. This set includes glycans described previously in literature for the LSDs included in this study [2,9,15,16,25,29-40] as well as the glycans found previously for galactosialidosis samples [26].

5.4.1 Urinary glycans in fucosidosis

Eight fucosylated oligosaccharides were detected in the urine sample of a fucosidosis patient, and the EIC of four of these fucosyl oligosaccharides are shown in Fig. 5-1. The neutral, fucosylated oligosaccharides were observed in an early retention time window (7 to 15 min), while the acidic species HNSF resulted in signals between 22 and 25 min. In order to enable relative quantification of the oligosaccharides, the signals were normalized to the overall intensity of detected MS signals. Glycan species were characterized by tandem mass spectrometry as exemplified for the fucosyl disaccharide Fuc-HexNAc which had a relative abundance of 10.6% (Table 5-2; Fig. 5-2). The MS/MS fragmentation spectrum (Fig. 5-2) showed Z_1 and B_1 fragments as well as a prominent signal arising from the loss of water (m/z 372.1). Cross-ring cleavages at m/z 229.0 ($^{0,4}A_2$), 259.0 ($^{0,3}A_2$), and 289.0 ($^{0,2}A_2$) suggest a 1-6 linkage for the fucose residue [41-43]. From the total set of 54 glycan compositions observed in this study, 17 were found to be present in the fucosidosis sample (see Supplementary materials Table S5-1) resulting in a glycan fingerprint as shown in Fig. 5-3a. Of the eight fucosylated oligosaccharides detected, three have already been previously shown to be related to fucosidosis [2,29,30,37,44].




Figure 5-1. Separation of oligosaccharides in urine of a fucosidosis patient. H = hexose, N = N-acetylhexosamine, F = fucose, S = N-acetylneuraminic acid, BPC = base peak chromatogram.




Figure 5-2. Positive-ion fragmentation mass spectrum of the monosodiated disaccharide HexNAc₁Fuc₁ (precursor ion at m/z 390.2) from urine of a fucosidosis patient. Red triangle = fucose, blue square = *N*-acetylglucosamine.

5.4.2 Urinary glycans in α -mannosidosis

Three urine samples of three different α -mannosidosis patients from two different families were analyzed. In all three samples, 17 endo- β -*N*-acetylglucosaminidase cleavage products of mannose-rich oligosaccharides of composition Hex₂₋₉HexNAc₁ were detected [33,45] (Table 5-2, Supplementary materials Table S5-2). The proposed structures are derived from literature [32,33,45] as well as from the obtained tandem MS data. An example of a fragment ion spectrum of the major Hex₃HexNAc₁ isomer is shown in Fig. 5-4. The $^{0,2}A_3$ and $^{2,4}A_3$ ions are typical for a 4-substituted HexNAc at the reducing end [41-43]. The cross-ring fragment $^{0,3}A_2$ (m/z 275.2) is indicative for a 6-substituted hexose [41-43]. The $B_2Y_{2\alpha}$ ion (D-ion, m/z 347.3) reveals the composition of the 6-antenna [42]. Histograms giving the relative abundances of the observed glycans are shown in Figs. 5-3b,c,d. The three urine samples resulted in very similar profiles including a prominent signal corresponding to Hex₂HexNAc₁. The whole set of oligomannosidic structures was detected (Hex₂₋₉HexNAc₁) showing decreasing signals with increasing size.

5.4.3 Urinary glycans in G_{M1}-gangliosidosis

Extracted ion chromatograms of the disease-related glycans found in the urine of a G_{M1}-gangliosidosis patient are represented in Fig. 5-5. Twenty glycan compositions were detected, and six of those structures with the composition Hex₃₋₇HexNAc₂₋₅ are presumably disease-related (Table 5-2, Supplementary materials Table S5-3). The compositions as well as the tandem mass spectrometric data (see Supplementary materials Table S5-3) suggest these glycans to be endo- β -*N*-acetylglucosaminidase cleavage products of complex type *N*-glycans. Composition Hex₃HexNAc₂ was interpreted as monoantennary and Hex₅HexNAc₃ as diantennary structure.

Table 5-2. Oligosaccharide species detected in urine samples U1–U8 and their relative area. Comp., composition; Fuc., fucosidosis; GM1-gang., C₁-gangliosidosis; Sial., sialidosis.

Comp.	Registered m/z	Charge state	Fuc.	C _{m1} -gang.		C _{m2} -gangliosidosis			α-Mannosidosis				Sial.
				U1	U2	U3	U4	U5	U6	U7			
H ₁ F	349.2	[M+Na] ⁺	2.6%	0.6%		0.7%	16.0%	1.9%	1.6%	2.1%	1.7%		
H ₂ F	511.3	[M+Na] ⁺	0.3%	4.4%		0.5%	0.7%	0.2%	0.0%	0.3%	2.8%		
N ₁ F	390.2	[M+Na] ⁺	10.6%	0.0%		0.2%	0.0%	0.1%	0.0%	0.0%	0.3%		
H ₁ N ₁ F	552.5	[M+Na] ⁺	14.1%	0.6%		0.5%	0.2%	0.6%	0.2%	1.2%	1.2%		
H ₂ N ₁ F	714.5	[M+Na] ⁺	0.3%	0.9%		0.6%	0.8%	0.9%	0.3%	1.0%	1.1%		
H ₂ N ₂ F	860.5	[M+Na] ⁺	2.3%	0.0%		0.2%	0.1%	0.7%	3.2%	0.7%	0.0%		
H ₃ N ₁ F	1079.4	[M+Na] ⁺	1.3%	0.0%		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		
H ₁ N ₂ F	865.4	[M-H+2Na] ⁺	2.3%	0.0%		0.3%	0.0%	0.0%	0.0%	0.0%	0.0%		
H ₂ N ₂	771.5	[M+Na] ⁺	1.6%	0.0%		7.6%	7.6%	0.2%	0.1%	0.1%	0.3%		
H ₃ N ₂	933.5; 478.3	[M+Na] ⁺ ; [M+2Na] ²⁺	0.0%	16.2%		0.6%	0.4%	0.1%	0.2%	0.1%	6.5%		
H ₄ N ₂	1095.5	[M+Na] ⁺	0.7%	0.7%		0.0%	0.0%	0.1%	0.0%	0.0%	0.0%		
H ₄ N ₃	1298.5; 660.9	[M+Na] ⁺ ; [M+2Na] ²⁺	0.0%	0.5%		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		
H ₃ N ₃	1136.5; 580.0	[M+Na] ⁺ ; [M+2Na] ²⁺	0.0%	0.0%		8.0%	8.2%	0.0%	0.0%	0.0%	0.0%		
H ₃ N ₄	1339.4; 681.2	[M+Na] ⁺ ; [M+2Na] ²⁺	0.0%	0.0%		14.8%	15.5%	0.0%	0.0%	0.0%	0.0%		
H ₂ N ₃	974.6	[M+Na] ⁺	0.0%	0.0%		1.3%	1.2%	0.0%	0.0%	0.0%	0.0%		
H ₃ N ₃	1460.6; 742.1	[M+Na] ⁺ ; [M+2Na] ²⁺	0.0%	271%		0.0%	0.0%	0.0%	0.0%	0.2%	0.3%		
H ₆ N ₄	924.5	[M+Na] ⁺	0.0%	3.0%		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		
H ₇ N ₅	1107.0	[M+2Na] ²⁺	0.0%	0.3%		0.0%	0.0%	0.0%	0.0%	0.0%	0.0%		
H ₁ N	406.2	[M+Na] ⁺	1.4%	1.9%		3.6%	2.5%	0.0%	0.0%	0.0%	5.4%		
H ₂ N	568.4	[M+Na] ⁺	0.5%	0.3%		0.9%	1.8%	53.7%	50.1%	54.7%	1.1%		
H ₃ N	730.4	[M+Na] ⁺	0.0%	0.5%		0.4%	0.5%	14.1%	13.9%	15.2%	1.3%		
H ₄ N	892.5	[M+Na] ⁺	0.0%	0.0%		0.3%	0.3%	11.9%	13.5%	12.6%	1.4%		
H ₅ N	1054.5	[M+Na] ⁺	0.0%	0.0%		0.2%	0.0%	3.2%	4.0%	3.2%	0.0%		
H ₆ N	1216.5	[M+Na] ⁺	0.0%	0.0%		0.0%	0.0%	1.3%	1.5%	1.2%	0.0%		
H ₇ N	1378.5; 700.9	[M+Na] ⁺ ; [M+2Na] ²⁺	0.0%	0.0%		0.0%	0.0%	0.6%	0.7%	0.5%	0.0%		

H ₈ N	1540.4; 782.0	[M+Na] ⁺ ; [M+2Na] ²⁺	0.0%	0.0%	0.0%	0.5%	0.4%	0.0%
H ₉ N	1702.8; 863.0	[M+Na] ⁺ ; [M+2Na] ²⁺	0.0%	0.0%	0.0%	0.2%	0.3%	0.0%
HS	516.3	[M+H+2Na] ⁺	0.8%	0.0%	0.2%	0.1%	0.0%	1.0%
H ₂ S	678.5; 656.5	[M+H+2Na] ⁺ ; [M+Na] ⁺	2.7%	1.5%	2.3%	0.7%	0.6%	2.2%
NS		NS	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
HNS	719.5; 697.6	[M+H+2Na] ⁺ ; [M+Na] ⁺	2.9%	0.7%	1.6%	0.4%	0.5%	2.7%
N ₂ S	760.3; 738.4	[M+H+2Na] ⁺ ; [M+Na] ⁺	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%
H ₃ N ₂ S	1246.8; 635.1	[M+H+2Na] ⁺ ; [M+H+3Na] ²⁺	0.0%	0.0%	0.0%	0.0%	0.0%	18.7%
H ₃ N ₃ S	898.3; 887.6	[M+H+3Na] ²⁺ ; [M+2Na] ²⁺	0.0%	0.2%	0.0%	0.0%	0.0%	3.2%
H ₃ N ₃ S ₂	1055.1; 1044.1	[M+2H+4Na] ²⁺ ; [M+H+3Na] ²⁺	0.0%	0.0%	0.0%	0.0%	0.0%	8.7%
H ₆ N ₄ S ₂	1237.4	[M+2H+4Na] ²⁺	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
H ₆ N ₄ S ₃			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
H ₇ N ₅ S ₂			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
H ₇ N ₅ S ₃			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
H ₃ (SO ₃)N ₂ S	1348.2; 674.5	[M+2H+3Na] ⁺ ; [M+H+3Na] ²⁺	0.0%	0.0%	0.0%	0.0%	0.0%	2.4%
H ₃ (SO ₃)N ₃ S	1854.3; 949.4	[M+H+2Na] ⁺ ; [M+2H+4Na] ²⁺	0.0%	0.0%	0.0%	0.0%	0.0%	0.9%
H ₅ (SO ₃)N ₃ S ₂	2166.6; 1083.8	[M+2H+3Na] ⁺ ; [M+H+3Na] ²⁺	0.0%	0.0%	0.0%	0.0%	0.0%	1.0%
H ₆ (SO ₃)N ₄ S ₃			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
H ₂ NS			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
S ₂			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
HX			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
H ₂ X			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
HNX	606.5; 584.3	[M+H+2Na] ⁺ ; [M+Na] ⁺	0.0%	0.5%	0.0%	0.0%	0.0%	0.0%
HNSX			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
SX			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
N ₂ NeuGc			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
H ₂	365.2	[M+Na] ⁺	48.7%	35.8%	46.7%	71%	4.9%	26.6%
H ₃	527.3	[M+Na] ⁺	5.2%	3.8%	6.2%	0.9%	2.9%	6.5%
H ₄	689.5	[M+Na] ⁺	1.6%	0.5%	2.2%	0.4%	1.0%	2.8%




Figure 5-3. Histograms showing the relative abundance of the detected glycans in the urine sample (Table 5-1) of lysosomal storage disorders fucosidosis (a), α -mannosidosis (b, c, and d). H or white circle = hexose, N or white square = *N*-acetylhexosamine, F or red triangle = fucose, S or purple diamond = *N*-acetylneuraminic acid, NeuGc = *N*-glycolylneuraminic acid, X = hexonic acid, SO₃ = sulfate, yellow circle = galactose, green circle = mannose, blue square = *N*-acetylglucosamine.

Species carrying additional Hex₁HexNAc₁ units were found to be attached resulting in Hex₆HexNAc₄ and Hex₇HexNAc₅ species carrying more antennae as well as LacNAc repeats [9,34,35]. In addition, a relatively low amount of a trisaccharide with the composition Hex₁HexNAc₁HexonA₁ was detected (Table 5-2). A histogram showing the relative abundance of the observed glycans is given in Fig. 5-3e with high signals corresponding to Hex₃HexNAc₂ and Hex₅HexNAc₃. The tandem MS spectrum of the disodiated diantennary *N*-glycan with the composition Hex₅HexNAc₃ (*m/z* 742.1) is shown in Fig. 5-6. The cross-ring fragments ^{0,2}A₅ and ^{2,4}A₅ are typical for a 4-substituted reducing end HexNAc [41-43]. The fragment ion B₄Y_{2α} (D-ion, *m/z* 712.3) reveals the composition of the 6-antenna [42]. The characterization of the two well-separated isomers with the composition Hex₃HexNAc₂ has been reported earlier [25].




Figure 5-3 Continued. G_{M1}-gangliosidosis (e), G_{M2}-gangliosidosis (f and g), and sialidosis (h). H or white circle = hexose, N or white square = N-acetylhexosamine, F or red triangle = fucose, S or purple diamond = N-acetylneuraminic acid, NeuGc = N-glycolylneuraminic acid, X = hexonic acid, SO₃ = sulfate, yellow circle = galactose, green circle = mannose, blue square = N-acetylglucosamine.

5.4.4 Urinary glycans in G_{M2}-gangliosidosis

The analysis of the urine samples of two G_{M2}-gangliosidosis patients revealed 11 G_{M2}-gangliosidosis-related glycan isomers (Table 5-2, Supplementary materials Table S5-4) with the composition Hex₂₋₃HexNAc₂₋₄. The proposed structures reported in Supplementary materials Table S5-4 are based on our MS/MS results and on the known urinary oligosaccharides related to β -hexosaminidase deficiency in G_{M2}-gangliosidosis [15,16]. Hex₂HexNAc₂ corresponds to a




Figure 5-4. Positive-ion fragmentation mass spectrum of the monosodiated tetrasaccharide $\text{Man}_3\text{GlcNAc}_1$ (precursor ion at m/z 730.6) from urine of an α -mannosidosis patient. Green circle = mannose, blue square = *N*-acetylglucosamine.




Figure 5-5. Separation of oligosaccharides in urine of a G_{M1} -gangliosidosis patient. H = hexose, N = *N*-acetylhexosamine, BPC = base peak chromatogram.




Figure 5-6. Positive-ion fragmentation mass spectrum of the disodiated diantennary oligosaccharide Hex₅HexNAc₃ (precursor ion at m/z 742.1) from urine of a G_{M1}-gangliosidosis patient. Yellow circle = galactose, green circle = mannose, blue square = *N*-acetylglucosamine.

monoantennary, Hex₂HexNAc₃ to a bisected monoantennary, Hex₃HexNAc₃ to a diantennary, and Hex₃HexNAc₄ to a triantennary or bisected diantennary structure [16]

Fig. 5-7 shows an excellent example of the isomeric separation of the two reported monoantennary glycans (Hex₂HexNAc₂, m/z 771.5). The EIC corresponding to Hex₂HexNAc₂ (m/z 771.5) shows the separation of these isobaric structures (retention times 10.3 and 11.9 min; Fig. 5-7), and the MS/MS spectra are shown in Fig. 5-8. The observed series of B-ions are in accordance with a monosaccharide sequence of HexNAc-Hex-Hex-HexNAc for both isomers. Both oligosaccharides contain *N*-acetylhexosamine at the reducing end, which shows the cross-ring fragments ^{0.2}A₄ (m/z 670) and ^{2.4}A₄ (m/z 610) indicative for a 4-substituted *N*-acetylhexosamine [41-43]. The observed cross-ring fragments ^{0.2}A₃ (m/z 508), ^{0.3}A₃ (m/z 478), and ^{0.4}A₃ (m/z 448) observed for the adjacent hexose are typical for a 6-substitution. Based on the observed MS/MS data and literature data [15], glycan A was identified as the G_{M2}-gangliosidosis urinary tetrasaccharide GlcNAc(β1-2)Man(α1-6)Man(β1-4)GlcNAc. A lack of A₃ cross-ring fragments, which is typical for a 3-substituted sugar, indicates that glycan B is the isomer GlcNAc(β1-2)Man(α1-3)Man(β1-4)GlcNAc. Hence, the linkage-specific fragmentation allowed the assignment of the observed glycans to two urinary glycans related to G_{M2}-gangliosidosis [15]. Moreover, the isomeric separation is emphasized by the different elution times of the three isomers corresponding to Hex₃HexNAc₃ registered in monosodiated (m/z 1136.5) as well as disodiated (m/z 580.0) form. Figs. 5-3f and 5-3g show the relative abundance of the detected glycans for the two urine samples. In both samples, a high relative abundance of Hex₂HexNAc₂ (both samples 7.6%), Hex₂HexNAc₃ (1.3% and 1.2%), Hex₃HexNAc₃ (8.0% and 8.2%), and Hex₃HexNAc₄ (14.8% and 15.5%) was observed.




Figure 5-7. Separation of oligosaccharides in urine of a G_{M2} -gangliosidosis patient. Fragment ion spectra of the species A and B is shown in Fig. 5-8. F = fucose, H = hexose, N = *N*-acetylhexosamine, BPC = base peak chromatogram.

5.4.5 Urinary glycans in sialidosis

Analysis of the urine of a sialidosis patient revealed eight disease-related sialylated oligosaccharides (Table 5-2, Supplementary materials Table S5-5). Structures with a high relative abundance such as $Hex_3HexNAc_2$ (6.5%), $HexHexNAc$ (5.4%), $Hex_3HexNAc_2Neu5Ac$ (18.7%), and $Hex_5HexNAc_3Neu5Ac_2$ (8.7%) were detected (Fig. 5-3h). The presence of sulfated sialyloligosaccharides $H_{3-5}SO_3N_{2-3}S_{1-2}$ is noteworthy [26].

5.5 DISCUSSION

Using a prototype capillary HPAEC-IPAD-MS system for analyzing a set of 54 glycans in eight urine samples from patients with lysosomal storage disorders such as fucosidosis, α -mannosidosis, G_{M1} -gangliosidosis, G_{M2} -gangliosidosis, and sialidosis (Table 5-1), we were able to find disease-related glycan structures. In addition, we identified glycan structures that are most probably diet- (human milk) or blood-group-related and are not related to the investigated disorders [37,46-51] (see Table 5-2 and Supplementary materials tables S5-1–S5-5). All urine samples, except for those of the mannosidosis patients, were found to contain a high relative amount




Figure 5-8. Positive-ion fragmentation mass spectra of two isomeric monosodiated tetrasaccharides $\text{Hex}_2\text{HexNAc}_2$ (precursor ion at m/z 771.5) from urine of a G_{M2} -gangliosidosis patient. The separation of A and B is shown in Fig. 5-7. Green circle = mannose, blue square = *N*-acetylglucosamine.

of dihexose which is most likely a dietary product [37,46,47]. The presence of dietary products in urine is not surprising. We reported in a previous research about free oligosaccharides such as lactose, sialylhexose, and sialyllactose that we detected as major abundant carbohydrates in control urine samples of four healthy individuals [26].

Detection was performed using an ion trap mass spectrometer which was operated in automatic tandem MS mode resulting in informative fragment ion spectra for many glycans. Linkage-specific fragment ions [41-43] together with the known structural selectivity of high-performance anion-exchange chromatography [52-54] and literature knowledge on urinary oligosaccharides of LSDs [30,55] made it possible to assign structures to most of the observed chromatographic signals.

Literature on fucosidosis reports that fucosylglycoasparagines are the most abundant glycoconjugates found in the urine of these patients [2,56]. These glycoconjugates are not expected to show up in our analysis, as they will presumably adsorb to or pass through the membrane of the online desalter. This phenomenon is due to the high negative charge density of the fiber wall which is expected to result in strong interactions with cations such as glycopeptides entering the desalter [25]. Instead, we detected free fucosylsaccharides in the urine samples. The most abundant one is the disaccharide $\text{Fuc}(\alpha 1-6)\text{GlcNAc}$ (Table 5-2, Supplementary materials Table S5-1, Figs. 5-2 and 5-3A) which is characteristic for this disorder [2,56,57]. Moreover, a

trisaccharide with composition $\text{Hex}_1\text{HexNAc}_1\text{Fuc}_1$ was found for fucosidosis (Fig. 5-3a). This trisaccharide is possibly the previously reported $\text{GalNAc}(\alpha 1-3)[\text{Fuc}(\alpha 1-2)]\text{Gal}$ [56]. In addition, Tsay *et al.* [58] and Nishigaki *et al.* [59] reported the presence of a fucosylated decasaccharide, however, this structure has neither been detected by us nor by Strecker *et al.* [56].

Moreover, 17 endo- β -*N*-acetylglucosaminidase cleavage products including chromatographically separated isomers were detected in all three urine samples of patients suffering from α -mannosidosis (see Supplementary materials Table S5-2). These findings are in agreement with previous results reported by Matsuura *et al.* [33]. The authors identified in their study a similar number of endo- β -*N*-acetylglucosaminidase cleavage products [33]. However, while we observed three $\text{Hex}_4\text{HexNAc}_1$ isomers, three $\text{Hex}_5\text{HexNAc}_1$ isomers, and one $\text{Hex}_7\text{HexNAc}_1$ isomer, these authors found two, two, and three isomers, respectively (see Supplementary materials Table S5-2).

One of the three isomers of $\text{Hex}_3\text{HexNAc}_3$ found in the urine samples from patients suffering from $\text{G}_{\text{M}2}$ gangliosidosis is in accordance with the diantennary structure with the core trimannose previously described by Strecker *et al.* [15,60] while the other two isomers are probably monoantennary structures decorated with a $\text{GlcNAc}(\beta 1-3)\text{Gal}(\beta 1-4)\text{GlcNAc}(\beta 1-2)$ antenna. In the current study, we reported eight glycan structures that are related to sialidosis (see Supplementary materials Table S5-5). Of these eight glycans, five have been previously identified in sialidosis [39,40,50,61]. We interpreted the structure of the glycan with the composition $\text{Hex}_1\text{HexNAc}_1\text{Neu5Ac}_1$ as $\text{Neu5Ac}(\alpha 2-3/6)\text{Gal}(\beta 1-4)\text{GlcNAc}$ and being related to sialidosis [50], although, based on our data, we cannot exclude that $\text{Neu5Ac}(\alpha 2-3/6)\text{Gal}(\beta 1-4)\text{GlcNAc}$ might be sialyllactosamine from milk [37,62,63]. All sialidosis-relevant carbohydrate structures described here are terminated with sialic acid residues, in accordance with the primary defect in exo- α -sialidase. In addition, three O-sulfated oligosaccharides with terminal sialic acid residues were detected in the urine sample (Table 5-2) showing structures previously detected by us in galactosialidosis [26]. This may imply that the O-sulfated carbohydrates reported here are indeed related to the exo- α -sialidase deficiency found in both galactosialidosis and sialidosis. MS detection in the positive ion mode is known to be less sensitive for negatively charged glycans such as sialyl- and O-sulfated-oligosaccharides. Therefore, this sample has also been analyzed in the negative ion mode and indeed more sialylated-, O-sulfated-glycans, and glycans having reducing end aldohexonic acid residue were observed due to the improved sensitivity for the detection of negatively charged molecules (data not shown).

All together, this publication shows the value of capillary HPAEC-IPAD-MS for analyzing oligosaccharides in clinical urine samples without the need for derivatization. This prototype analytical system features femtomol sensitivity for both pulsed amperometric detection and mass spectrometric detection [25] allowing the relatively low abundant O-sulfated-glycan moieties to be detected. In contrast to other liquid chromatography methods relying on reducing end labeling for detection and/or separation [64,65] HPAEC-IPAD as well as HPAEC-MS do not depend on glycan labeling. Consequently, we were able to detect an oxidized oligosaccharide with an innermost aldohexonic acid residue in the $\text{G}_{\text{M}1}$ -ganglioside urine sample. Moreover, the setup used in this study enables the separation of isomeric glycans. Based on the efficient fragment ion analysis using an ion trap instrument, informative fragment spectra of sodium adducts can be obtained with minute amounts of material, allowing insights into defects of glycoconjugates degradation, and investigation of metabolic and catabolic pathways.

Although the used instrumentation is a prototype, similar analyses can be performed using commercially available narrow bore ion chromatographs [66], with presumably less sensitivity due to the bigger dimensions and higher flow rates. The desalter in such a system is based on a flat semi-permeable cation exchange membrane and regenerated by electrolysis of water [67,68].

LC-MS in general and the here described method in particular are analytically powerful. In the current research paper, we demonstrated that the HPAEC-MS technology in combination with MS/MS information on structural isomers is suitable for determining characteristic glycan fingerprints in lysosomal storage diseases which may have diagnostic potential.

5.6 ACKNOWLEDGMENT

We would like to thank Dr. André Klein, Laboratoire de Biochimie et de Biologie Moléculaire, UAM de Glycopathologies, Centre de Biologie et Pathologie, Lille, France, for kindly providing a urine sample; Dr. Crina Balog for her support with data analysis; Rob Bruggink for providing essential input for producing the capillary desalter; Chris Pohl, Yan Liu, Victor Barretto, and Franck van Veen from Thermo Fisher Scientific for essential support of this research.

SUPPLEMENTARY MATERIAL

Table S5-1. Oligosaccharide species detected in the fucosidosis sample U1. Comp., composition; Ret., retention; Rel. area., relative area.

	Comp.	Registered m/z	Charge state	Ret. time (min)
Disease related glycans	NF	390.2	[M+Na] ⁺	8.8
	H ₂ NF	714.5	[M+Na] ⁺	9.1
	H ₃ N ₂ F	1079.4	[M+Na] ⁺	9.2
	HNSF	865.4	[M-H+2Na] ⁺	22.7
				24.0
Other glycans	H ₂ NF ₂	860.5	[M+Na] ⁺	8.9
	HF	349.2	[M+Na] ⁺	8.9
	H ₂ F	511.3	[M+Na] ⁺	9.4
	HNF	552.5	[M+Na] ⁺	8.9
	H ₂	365.2	[M+Na] ⁺	9.7
	H ₃	527.3	[M+Na] ⁺	11.0
				12.7
				23.6
	H ₄	689.5	[M+Na] ⁺	23.9
				25.3
	HN	406.2	[M+Na] ⁺	9.4
	H ₂ N	568.4	[M+Na] ⁺	9.8
	H ₂ N ₂	771.5	[M+Na] ⁺	14.3
	HNS	719.5/ 697.2	[M+Na] ⁺ [M-H+2Na] ⁺	25.2
	HS	516.1	[M-H+2Na] ⁺	25.6
	H ₂ S	678.5	[M-H+2Na] ⁺	25.7

Fragment ions	Rel. area	
	U1	Proposed structure
244.0 N; 226.0 N-18; 187.2 F; 169.1 F-18	10.6%	Fuc(α 1-6)GlcNAc [2,29,30,37,44]
	0.3%	
	1.3%	
719.5 HNS; 552.4 HNF; 534.3 HNF-18; 516.2 HS; 498.0 HS-18; 405.9 HN; 388.1 HN-18; 336.0 S-18; 318.1 S-2x18	0.8%	NeuAc(α 2-3/6)Gal(β 1-4)[Fuc(α 1-3)]GlcNAc
552.2 HNF; 534.1 HNF-18; 516.0 HS; 498.2 HS-18; 354.2 S; 336.0 S-18	1.6%	
714.4 H ₂ NF; 696.1 H ₂ NF-18; 657.3 H ₂ F ₂ ; 568.3 H ₂ N; 552.4 HNF; 550.4 H ₂ N-18; 534.3 HNF-18; 532.5 H ₂ N-2x18; 405.9 HN; 388.1 HN-18; 370.3 HN-2x18; 349.1 HF; 244.0 N	2.3%	GalNAc(α 1-3)[Fuc(α 1-2)]Gal(β 1-4)[Fuc(α 1-3)]Glc [37]
	2.6%	Fuc(α 1-2)Gal [37]
	0.3%	Fuc[Gal(β 1-4)Glc [37,46,47]
406.1 HN; 388.1 HN-18; 372.1 NF-18; 244.0 N; 226.0 N-18; 208.0 N-2x18; 203.0 H; 187.1 F; 185.0 H-18; 169.0 F-18	14.2%	GalNAc(α 1-3)[Fuc(α 1-2)]Gal [37]
203.0 H; 185.0 H-18	49.1%	
365.1 H ₂ ; 347.1 H ₂ -18; 203.1 H; 185.0 H-18	2.4%	
365.1 H ₂ ; 347.1 H ₂ -18; 203.1 H; 185.0 H-18	1.5%	
365.1 H ₂ ; 347.1 H ₂ -18; 203.0 H; 185.0 H-18	1.4%	
527.3 H ₃ ; 509.2 H ₃ -18; 365.3 H ₂ ; 346.9 H ₂ -18	0.5%	
527.3 H ₃ ; 509.2 H ₃ -18; 365.1 H ₂ ; 347.0 H ₂ -18	1.2%	
	1.4%	
	0.5%	
	1.6%	
516.2 HS; 498.1 HS-18; 406.1 HN; 354.0 S; 336.0 S-18; 226.0 N	3.0%	NeuAc(α 2-3/6)Gal(β 1-4)GlcNAc [50]
	0.8%	Neu5Ac-Hex
498.2 HS-18; 354.0 S; 365.1 H ₂ ; 336.0 S-18	2.7%	NeuAc(α 2-3/6)Gal(β 1-4)Glc [50]

Table S5-2. Oligosaccharide species detected in the α -mannosidosis samples U5, U6, and U7. Comp., composition; Ret., retention.

	Comp.	Registered m/z	Charge state	Ret. time (min)	Fragment ions
Disease related glycans	H ₂ N	568.4	[M+Na] ⁺	5.8	406.2 HN; 388.1 HN-18; 365.2 H ₂ ; 347.2 H ₂ -18; 244.1 N; 226.0 N-18; 203.1 H
	H ₃ N	730.4	[M+Na] ⁺	8.1	568.3 H ₂ N; 550.3 H ₂ N-18; 527.3 H ₃ ; 509.2 H ₃ -18; 388.2 HN-18; 365.1 H ₂ ; 347.2 H ₂ -18; 329.0 H ₂ -2x18; 244.1 N; 226.0 N-18
				8.9	527.2 H ₃ ; 509.2 H ₃ -18; 406.2 HN; 388.1 HN-18; 365.3 H ₂ ; 347.2 H ₂ -18; 329.2 H ₂ -2x18; 244.2 N; 226.2 N-18
	H ₄ N	892.5	[M+Na] ⁺	10.6	730.2 H ₃ N; 712.3 H ₃ N-18; 689.4 H ₄ ; 671.3 H ₄ -18; 527.1 H ₃ ; 509.3 H ₃ -18; 406.3 HN; 347.1 H ₂ -18
				12.8	730.2 H ₃ N; 712.3 H ₃ -18; 689.3 H ₄ ; 671.3 H ₄ -18; 568.4 H ₂ N; 550.3 H ₂ N-18; 527.2 H ₃ ; 509.3 H ₃ -18; 491.3 H ₃ -2x18; 406.2 HN; 388.3 HN-18; 365.3 H ₂ ; 347.2 H ₂ -18; 329.2 H ₂ -2x18; 244.2 N
				15.4	730.2 H ₃ N; 712.3 H ₃ N-18; 689.3 H ₄ ; 671.3 H ₄ -18; 568.2 H ₂ N; 527.3 H ₃ ; 509.2 H ₃ -18; 491.1 H ₃ N-2x18; 406.0 HN; 388.1 HN-18; 365.1 H ₂ ; 347.2 H ₂ -18
	H ₅ N	1054.5	[M+Na] ⁺	15.9	874.5 H ₄ N-18; 851.3 H ₅ ; 833.4 H ₅ -18; 712.8 H ₃ N-18; 689.3 H ₄ ; 671.3 H ₄ -18; 568.3 H ₂ N; 550.2 H ₂ N-18; 527.1 H ₃ ; 509.3 H ₃ -18; 491.2 H ₃ -2x18
				16.7	851.4 H ₅ ; 833.4 H ₅ -18; 712.3 H ₃ N-18; 689.4 H ₄ ; 671.3 H ₄ -18; 653.4 H ₄ -2x18; 568.3 H ₂ N; 527.1 H ₃ ; 509.3 H ₃ -18; 365.1 H ₂ ; 347.1 H ₂ -18
				18.6	892.3 H ₄ N; 851.3 H ₅ ; 833.1 H ₅ -18; 730.3 H ₃ N; 689.3 H ₄ ; 671.4 H ₄ -18; 568.4 H ₂ N; 550.0 H ₂ N-18; 509.2 H ₃ -18; 491.1 H ₃ -2x18; 365.1 H ₂ ; 346.9 H ₂ -18
	H ₆ N	1216.5	[M+Na] ⁺	19.2	1054.3 H ₅ N; 1036.4 H ₅ N-18; 1013.4 H ₆ ; 995.4 H ₆ -18; 892.4 H ₄ N; 874.4 H ₄ N-18; 851.3 H ₅ ; 833.3 H ₅ -18; 730.3 H ₃ N; 671.4 H ₄ -18; 653.3 H ₄ -2x18; 568.3 H ₂ N; 527.3 H ₃ ; 509.3 H ₃ -18; 491.2 H ₃ -2x18
				19.9	1054.5 H ₅ N; 1036.4 H ₅ N-18; 1013.3 H ₆ ; 995.4 H ₆ -18; 892.3 H ₄ N; 851.3 H ₅ ; 833.4 H ₅ -18; 730.2 H ₃ N; 689.3 H ₄ ; 671.4 H ₄ -18; 527.5 H ₃ ; 509.1 H ₃ -18; 347.1 H ₂ -18
				21.4	
	H ₇ N	700.9 1378.5	[M+2Na] ²⁺ [M+Na] ⁺	21.7	1198.3 H ₆ N-18; 1175.4 H ₇ ; 1157.3 H ₇ -18; 1054.5 H ₅ N; 1036.4 H ₅ N-18; 1013.2 H ₆ ; 995.4 H ₆ -18; 892.3 H ₄ N; 874.3 H ₄ N-18; 851.2 H ₅ ; 833.1 H ₅ -18; 712.4 H ₃ N; 689.4 H ₄ ; 671.4 H ₄ -18; 509.1 H ₃ -18; 491.3 H ₃ -2x18
	H ₈ N	782.0 1540.4	[M+2Na] ²⁺ [M+Na] ⁺	15.8	
		23.9	671.1 H ₄ -18; 346.9 H ₂ -18		
		25.5			
	H ₉ N	863.0 1702.8	[M+2Na] ²⁺ [M+Na] ⁺	25.8	

Relative area			Proposed structure
U5	U6	U7	
52.9%	49.6%	53.7%	Man(α 1-2)Man(α 1-3)Man(β 1-4)GlcNAc [31-33,45]
1.2%	1.4%	1.0%	Man(α 1-6)[Man(α 1-3)]Man(β 1-4)GlcNAc [33,45]
12.7%	12.3%	13.9%	Man(α 1-2)Man(α 1-3)Man(β 1-4)GlcNAc [31-33,45]
0.4%	0.4%	0.3%	
10.7%	12.5%	11.1%	Man(α 1-2)Man(α 1-2)Man(α 1-3)Man(β 1-4)GlcNAc [32,33,45]
0.6%	0.5%	0.9%	Man(α 1-3)Man(α 1-6)[Man(α 1-3)]Man(β 1-4)GlcNAc [32]
0.7%	0.6%	0.7%	Man(α 1-3)Man(α 1-6)[Man(α 1-2)Man α 1-3)]Man(β 1-4)GlcNAc [32,33,45]
2.4%	3.4%	2.4%	Man(α 1-6)[Man(α 1-3)]Man(α 1-6)[Man(α 1-3)]Man(β 1-4)GlcNAc [32,33,45]
0.2%	0.1%	0.3%	
0.5%	0.6%	0.4%	Man(α 1-2)Man(α 1-6)[Man(α 1-3)]Man(α 1-6)[Man(α 1-3)]Man(β 1-4)GlcNAc [32,33,45]
0.7%	0.9%	0.8%	Man(α 1-6)[Man(α 1-3)]Man(α 1-6)[Man(α 1-2)Man(α 1-3)]Man(β 1-4)GlcNAc [32,33,45]
0.1%	0.1%	0.2%	Man(α 1-2)Man(1-6)[Man(α 1-3)]Man(α 1-6)[Man α 1-3)]Man(β 1-4)GlcNAc [32,33,45]
0.6%	0.7%	0.5%	Man(α 1-2){Man(α 1-6)[Man(α 1-3)]Man(α 1-6)[Man(α 1-2)Man(α 1-3)]Man(β 1-4)GlcNAc [32,33,45]
0.1%	0.1%		
0.3%	0.4%	0.4%	2xMan(α 1-2){Man(α 1-6)[Man(α 1-3)]Man(α 1-6)[Man(α 1-2)Man(α 1-3)]Man(β 1-4)GlcNAc [32,33,45]
0.1%	0.1%		
0.2%	0.2%	0.3%	Man(α 1-2)Man(α 1-6)[Man(α 1-2)Man(α 1-3)]Man(α 1-6)[Man(α 1-2)Man(α 1-3)]Man(β 1-4)GlcNAc [32,33,45]

Table S5-2. continued

	Comp.	Registered m/z	Charge state	Ret. time (min)	Fragment ions
Other glycans	H ₂	365.2	[M+Na] ⁺	5.3	
	H ₃	527.3	[M+Na] ⁺	6.8	
				7.8	365.2 H ₂ ; 347.2 H ₂ -18; 203.0 H
				9.3	
				9.6	365.2 H ₂ ; 347.2 H ₂ -18; 203.0 H; 185.0 H-18
				15.7	
				16.8	
				17.5	365.2 H ₂ ; 347.3 H ₂ -18; 203.0 H; 185.1 H-18
				18.7	
				20.7	
	H ₄	689.4	[M+Na] ⁺	8.4	527.2 H ₃ ; 509.3 H ₃ -18; 365.2 H ₂ ; 347.2 H ₂ -18
				25.7	527.3 H ₃ ; 509.2 H ₃ -18; 365.2 H ₂ ; 347.2 H ₂ -18
	HN	406.3	[M+Na] ⁺	4.3	
	H ₂ N ₂	771.1	[M+Na] ⁺	10.2	
	H ₃ N ₂	933.5	[M+Na] ⁺	8	
	H ₄ N ₂	1095.5	[M+Na] ⁺	8	
				18.6	
	H ₅ N ₃	741.9	[M+2Na] ²⁺	21.4	
	H ₂ NF ₂	860.5	[M+Na] ⁺	4.1	714.3 H ₂ NF; 696.3 H ₂ NF-18; 657.4 H ₂ F ₂ ; 568.3 H ₂ N; 552.2 HNF; 550.2 H ₂ N-18; 534.3 HNF-18; 511.3 H ₂ F; 406.3 HN; 388.2 HN-18; 349.2 HF; 331.1 HF-18; 244.1 N
	HF	349.2	[M+Na] ⁺	3.9	
	H ₂ F	511.2	[M+Na] ⁺	9.8	
	NF	390.2	[M+Na] ⁺	3.1	
	HNF	552.4	[M+Na] ⁺	3.8	406.2 HN; 388.1 HN-18; 349.3 HF; 243.8 N; 226.2 N-18; 203.1 H
	HS	516.2	[M- H+2Na] ⁺	23.8	
	H ₂ NF	714.4	[M+Na] ⁺	4.6	
	HNS	697.4	[M+Na] ⁺	22.5	
		719.4	[M- H+2Na] ⁺		
	H ₂ S	656.5	[M+Na] ⁺	25.0	516,7 HS; 498,0/476,2 HS-18; 365.3 H ₂ ; 347.0 H ₂ -18;
		678.3	[M- H+2Na] ⁺		354,3/332.3 S; 336,2/314.1 S-18

Relative area			Proposed structure
U5	U6	U7	
7.0%	4.8%	3.2%	
0.2%	0.1%	0.2%	
0.3%	0.8%	0.5%	
	0.2%		
0.2%	0.5%	0.2%	
0.1%	0.2%		
0.0%	0.2%		
0.1%	0.5%	0.2%	
	0.3%		
	0.2%		
	0.4%	0.2%	
0.4%	0.6%	0.6%	
1.4%	1.0%	1.6%	
0.2%	0.1%	0.1%	
0.1%	0.2%		
		0.2%	
0.7%	3.1%	0.7%	
1.9%	1.6%	2.1%	GalNAc(α 1-3)[Fuc(α 1-2)]Gal(β 1-4)[Fuc(α 1-3)]Glc [37]
0.2%		0.3%	
0.1%			
0.6%	0.2%	1.2%	
0.1%	0.1%		GalNAc(α 1-3)[Fuc(α 1-2)]Gal [37]
0.9%	0.2%	0.9%	
0.4%	0.6%	0.5%	
0.7%	0.5%	0.6%	Neu5Ac(α 2-3)Gal(β 1-4)Glc [50]

Table S5-3. Oligosaccharide species detected in the G_{M1}-gangliosidosis sample U2. X, hexonic acid; GluconA, gluconic acid; Comp., composition; Ret., retention; Rel. area., relative area.

	Comp.	Registered m/z	Charge state	Ret. time (min)
Disease related glycans	H ₃ N ₂	933.5	[M+Na] ⁺	8.8
		478.3	[M+2Na] ²⁺	
		933.5	[M+Na] ⁺	12.8
		478.3	[M+2Na] ²⁺	
	H ₄ N ₂	1095.5	[M+Na] ⁺	15.0
		1095.5	[M+Na] ⁺	16.1
	H ₄ N ₃	1095.5	[M+Na] ⁺	21.0
		1298.5	[M+Na] ⁺	15.8
		660.9	[M+2Na] ²⁺	
		1298.5	[M+Na] ⁺	17.3
		660.9	[M+2Na] ²⁺	
	H ₅ N ₃	1460.6/ 742.1	[M+Na] ⁺ [M+2Na] ²⁺	20.9
	H ₆ N ₄	924.5	[M+2Na] ²⁺	22.7
		924.5	[M+2Na] ⁺	24.4
		924.5	[M+2Na] ⁺	25.7
	H ₇ N ₅	1107.0	[M+2Na] ²⁺	25.9

Fragment ions	Rel. area	
	U2	Proposed structure
730.4 H ₃ N ₂ ⁺ ; 712.3 H ₃ N ₂ -18; 568.3 H ₂ N ₂ ⁺ ; 550.3 H ₂ N ₂ -18; 406.2 HN ₂ ⁺ ; 388.2 HN ₂ -18; 365.2 H ₂ ⁺ ; 347.2 H ₂ -18	8.5%	Gal(β1-4)GlcNAc(β1-2)Man(α1-6) Man(β1-4)GlcNAc [9,25,34-36,44]
730.4 H ₃ N ₂ ⁺ ; 712.4 H ₃ N ₂ -18; 568.3 H ₂ N ₂ ⁺ ; 550.3 H ₂ N ₂ -18; 406.2 HN ₂ ⁺ ; 388.2 HN ₂ -18; 365.1 H ₂ ⁺ ; 347.2 H ₂ -18	7.2%	Gal(β1-4)GlcNAc(β1-2)Man(α1-3) Man(β1-4)GlcNAc [9,25,34-36,44]
933.3 H ₃ N ₂ ⁺ ; 915.1 H ₄ N ₂ -18; 892.2 H ₄ N ₂ ⁺ ; 874.3 H ₄ N ₂ -18; 753.4 H ₂ N ₂ -18; 730.3 H ₃ N ₂ ⁺ ; 712.1 H ₃ N ₂ -18; 568.2 H ₂ N ₂ ⁺ ; 550.3 H ₂ N ₂ -18; 532.2 H ₂ N ₂ -2x18; 527.3 H ₂ ⁺ ; 509.0 H ₃ -18; 406.4 HN ₂ ⁺ ; 388.2 HN ₂ -18; 365.1 H ₂ ⁺	0.2%	Gal(β1-4)GlcNAc(β1-2)Man(α1-6) [Man(α1-3)]Man(β1-4)GlcNAc [9]
933.3 H ₃ N ₂ ⁺ ; 892.2 H ₄ N ₂ ⁺ ; 874.4 H ₄ N ₂ -18; 730.3 H ₃ N ₂ ⁺ ; 568.2 H ₂ N ₂ ⁺ ; 550.3 H ₂ N ₂ -18; 509.2 H ₃ -18; 388.1 HN ₂ -18	0.1%	Man(α1-6)[Gal(β1-4)GlcNAc(β1-2) Man(α1-3)]Man(β1-4)GlcNAc Yamashita, 1981 49 /id][44]
	0.3%	
	0.2%	
1077.7/550.3 H ₄ N ₂ -18; 933.3 H ₃ N ₂ ⁺ ; 550.3 H ₂ N ₂ -18 or H ₄ N ₂ -9; 388.1 HN ₂ -18 or H ₂ N ₂ -9	0.4%	Gal(β1-4)GlcNAc(β1-2)[Gal(β1-4) GlcNAc(β1-4)]Man(α1-3)Man(β1-4) GlcNAc [35]
1298.6 H ₄ N ₂ ⁺ ; 1280.5 H ₄ N ₂ -18; 1257.6 H ₃ N ₂ ⁺ ; 1239.6 H ₃ N ₂ -18; 1095.6 H ₄ N ₂ ⁺ ; 1077.6 H ₄ N ₂ -18; 1059.6 H ₄ N ₂ -2x18; 933.5 H ₃ N ₂ ⁺ ; 915.4 H ₃ N ₂ -18; 892.5 H ₄ N ₂ ⁺ ; 874.6 H ₄ N ₂ - 18; 771.4 H ₃ N ₂ ⁺ ; 730.5 H ₃ N ₂ -18; 712.4 H ₃ N ₂ -18; 694.3 H ₃ N ₂ -2x18; 568.4 H ₃ N ₂ ⁺ ; 550.3 H ₂ N ₂ -18; 532.4 H ₂ N ₂ -2x18; 527.3 H ₂ ⁺ ; 514.1 H ₂ N ₂ -3x18; 509.3 H ₃ -18; 405.9 HN ₂ ⁺ ; 388.2 HN ₂ -18; 370.2 HN ₂ -2x18; 365.3 H ₂ ⁺ ; 347.2 H ₂ -18; 329.2 H ₂ -2x18; 244.0 N; 226.0 N-18; 208.1 N-2x18	26.2%	Gal(β1-4)GlcNAc(β1-2)Man(α1-6) [Gal(β1-4)GlcNAc(β1-2)Man(α1-3)] Man(β1-4)GlcNAc [9,34-36,44]
1442.7 H ₅ N ₂ -18; 1257.4 H ₃ N ₂ ⁺ ; 1239.5 H ₃ N ₂ -18; 892.3 H ₄ N ₂ ⁺ ; 651.7 H ₄ N ₂ -9; 570.8 H ₃ N ₂ -9; 388.2 HN ₂ -18	0.2%	
1622.4 H ₆ N ₂ ⁺ ; 1501.4 H ₄ N ₄ ⁺ ; 1460.5 H ₅ N ₂ ⁺ ; 1442.5 H ₅ N ₂ -18; 1424.4 H ₅ N ₂ -2x18; 1303.6 H ₅ N ₂ -2x18; 1298.6 H ₄ N ₂ ⁺ ; 1280.6 H ₄ N ₂ -18; 1257.6 H ₅ N ₂ ⁺ ; 1239.5 H ₅ N ₂ -18; 1118.5 H ₅ N ₂ -18; 1095.4 H ₄ N ₂ ⁺ ; 1077.6 H ₄ N ₂ -18; 1059.3 H ₄ N ₂ -2x18; 915.4 H ₃ N ₂ -18; 892.2 H ₄ N ₂ ⁺ ; 874.4 H ₄ N ₂ -18; 843.4 H ₅ N ₂ ⁺ ; 838.2 H ₄ N ₂ -3x18; 822.9 H ₄ N ₂ ⁺ ; 813.7 H ₅ N ₂ -9; 762.4 H ₄ N ₄ ⁺ ; 753.2 H ₂ N ₂ -18; H ₄ N ₄ -9; 741.9 H ₅ N ₂ ⁺ ; 735.2 H ₂ N ₂ -2x18; 732.9 H ₅ N ₂ -9; 730.2 H ₃ N ₂ ⁺ ; 712.3 H ₃ N ₂ -18; 660.8 H ₄ N ₂ ⁺ ; 640.3 H ₅ N ₂ ⁺ ; 570.3 H ₃ N ₂ ⁺ ; 568.3 H ₂ N ₂ ⁺ ; 559.3 H ₄ N ₂ ⁺ ; 552.6 H ₅ N ₂ -3x9; 550.2 H ₂ N ₂ -18; 406.2 HN ₂ ⁺ ; 388.2 HN ₂ -18; 347.2 H ₂ ⁺ ; 329.2 H ₂ -18	2.5%	Gal(β1-4)GlcNAc(β1-2)Man(α1-6) [Gal(β1-4)GlcNAc(β1-2)][Gal(β1-4) GlcNAc(β1-4)]Man(α1-3)]Man(β1-4) GlcNAc [9,34-36]
1604.5 H ₆ N ₂ -18; 1442.4 H ₅ N ₂ -18; 1257.4 H ₅ N ₂ ⁺ ; 1239.2 H ₅ N ₂ -18; 1095.4 H ₄ N ₂ ⁺ ; 1077.5 H ₄ N ₂ -18; 892.5 H ₄ N ₂ 874.4 H ₄ N ₂ -18; 822.8 H ₆ N ₂ ⁺ ; 753.3 H ₂ N ₂ -18; 730.3 H ₃ N ₂ ⁺ ; 550.2 H ₄ N ₂ ⁺ ; 388.2 HN ₂ -18	0.2%	Gal(β1-4)GlcNAc(β1-3)Gal(β1-4) GlcNAc(β1-2)Man(α1-6)[Gal(β1-4) GlcNAc(β1-2)Man(α1-3)]Man(β1-4) GlcNAc [9,34-36]
1825.7 H ₆ N ₂ ⁺ ; 1807.6 H ₆ N ₂ -18; 1663.6/843.4 H ₅ N ₄ ⁺ ; 1627.5 H ₅ N ₄ -2x18; 1622.6/822.7 H ₆ N ₂ ⁺ ; 1501.9 H ₄ N ₄ ⁺ ; 1460.6/741.7 H ₅ N ₂ ⁺ ; 1442.5 H ₅ N ₂ -18; 1298.5 H ₄ N ₂ ⁺ ; 1257.7 H ₅ N ₂ ⁺ ; 1239.5/631.4 H ₅ N ₂ -18; 1095.5 H ₄ N ₂ ⁺ ; 1077.4 H ₄ N ₂ -18; 1059.3 H ₄ N ₂ -2x18; 1016.9 H ₅ N ₂ -9; 1005.3 H ₇ N ₄ ⁺ ; 933.4/478.1 H ₃ N ₂ ⁺ ; 924.3 H ₆ N ₄ ⁺ ; 915.4 H ₆ N ₄ -9; 813.8 H ₅ N ₂ -9; 804.8 H ₄ N ₂ -2x9; 771.1 H ₂ N ₂ ⁺ ; 753.3 H ₂ N ₂ -18; 550.4 H ₂ N ₂ -18; 388.2 HN ₂ -18	0.2%	Gal(β1-4)GlcNAc(β1-6)][Gal(β1-4) GlcNAc(β1-2)]Man(α1-6)[Gal(β1-4) GlcNAc(β1-4)][Gal(β1-4)GlcNAc(β1- 2)]Man(α1-3)]Man(β1-4)GlcNAc [9,34,36]

Table S5-3. continued

	Comp.	Registered m/z	Charge state	Ret. time (min)
Other glycans	H ₂	365.1	[M+Na] ⁺	3.0
				4.6
				5.6
				7.1
				9.0
	HN	406.3	[M+Na] ⁺	5.3
	H ₃	527.3	[M+Na] ⁺	3.8
				6.5
				7.5
				14.0
				15.4
				16.5
				19.2
	H ₄	689.4	[M+Na] ⁺	22.1
	HF	349.2	[M+Na] ⁺	2.9
				4.6
	H ₂ F	511.3	[M+Na] ⁺	4.6
	H ₂ N	568.3	[M+Na] ⁺	6.2
	H ₃ N	730.4	[M+Na] ⁺	9.0
				14.8
	H ₂ NF	714.4	[M+Na] ⁺	3.8
	HNF	552.3	[M+Na] ⁺	3.8
	H ₂ S	656.4	[M+Na] ⁺	25.3
		678.4	[M-H+2Na] ⁺	
	HNS	697.4	[M+Na] ⁺	23.5
		719.4	[M-H+2Na] ⁺	
			[M+Na] ⁺	25.0
	H ₅ N ₃ S	887.8	[M+2Na] ²⁺	20.7
	HNX	584.3/	[M+Na] ⁺	20.6
		606.5	[M-H+2Na] ⁺	

Fragment ions	Rel. area	Proposed structure
	U2	
203.0 H	1.4%	
203.0 H	0.1%	
203.0 H; 185.0 H-18	30.4%	
203.1 H; 185.1 H-18	0.5%	
203.1 H; 185.0 H-18	2.3%	
226.1 N; 203.0 H; 185.0 H-18	1.8%	
365.1 H ₂ ; 347.1 H ₂ -18; 202.9 H	0.2%	
365.2 H ₂ ; 347.1 H ₂ -18; 203.0 H; 185.0 H-18	1.1%	
365.1 H ₂ ; 347.2 H ₂ -18; 203.1 H	0.2%	
365.2 H ₂ ; 347.2 H ₂ -18; 185.0 H-18	0.3%	
365.1 H ₂ ; 347.2 H ₂ -18; 203.0 H; 184.8 H-18	1.3%	
365.2 H ₂ ; 347.1 H ₂ -18; 202.9 H; 185.0 H-18	0.3%	
365.2 H ₂ ; 347.0 H ₂ -18; 203.0 H	0.2%	
527.1 H ₃ ; 509.2 H ₃ -18; 347.2 H ₂ -18; 203.0 H	0.1%	
527.2 H ₃ ; 509.2 H ₃ -18; 365.3 H ₂ ; 347.2 H ₂ -18; 203.1 H	0.4%	
	0.2%	
	0.4%	
365.2 H ₂ ; 347.2 H ₂ -18; 203.1 H; 185.1 H-18	4.2%	Fuc{Gal(β1-4)Glc [37,46,47,56]}
	0.3%	
	0.5%	
550.2 H ₂ N; 406.2 HN; 388.2 HN-18	0.5%	
568.2 H ₂ N; 550.3 H ₂ N-18; 406.2 HN; 388.2 HN-18; 203.1 H	3.2%	
568.3 H ₂ N; 550.4 H ₂ N-18; 406.2 HN; 388.2 HN-18; 226.1 N; 203.0 H	0.9%	
406.2 HN; 388.2 HN-18; 203.1 H	0.6%	GalNAc(α1-3)[Fuc(α1-2)]Gal [37]
476.1 HS-18; 365.3 H ₂ ; 347.2 H ₂ -18; 314.3 S-18; 202.9 H	1.4%	NeuAc(α2-3)Gal(β1-4)Glc [37,50]
516.2 HS; 336.1 S-18	0.2%	NeuAc(α2-6)Gal(β1-4)GlcNAc [37,50]
539.1 NS-18; 406.5 HN; 226.0 N	0.4%	
	0.2%	
	0.4%	

Table S5-4. Oligosaccharide species detected in the G_{M2}-gangliosidosis samples U3 and U4. Comp., composition; Ret., retention.

	Comp.	Registered m/z	Charge state	Ret. time (min)
Disease related glycans	H ₂ N ₂	771.5	[M+Na] ⁺	10.3
		771.5	[M+Na] ⁺	11.9
	H ₃ N ₃	1136.5	[M+Na] ⁺	15.1
		580.0	[M+2Na] ²⁺	
		1136.5	[M+Na] ⁺	16.8
		580.0	[M+2Na] ²⁺	
	H ₃ N ₄	1136.5	[M+Na] ⁺	18.1
		580.0	[M+2Na] ²⁺	
		681.2	[M+2Na] ²⁺	10.0
		1339.4	[M+Na] ⁺	12.9
		681.2	[M+2Na] ²⁺	
		681.2	[M+2Na] ²⁺	14.0
		681.2	[M+2Na] ²⁺	17.5
		1339.4	[M+Na] ⁺	20.0
		681.2	[M+2Na] ²⁺	
	H ₂ N ₃	974.6	[M+Na] ⁺	1.1

Fragment ions	Relative Area		Proposed structure
	U3	U4	
568.3 H ₂ N ₂ ; 550.3 H ₂ N-18; 406.1 HN; 388.1 HN-18; 365.1 H ₂ ; 347.1 H ₂ -18		1.6%	GlcNAc(β1-2)Man(α1-3)Man(β1-4) GlcNAc [15,16,44]
568.3 H ₂ N ₂ ; 550.3 H ₂ N-18; 406.1 HN; 388.1 HN-18; 365.1 H ₂ ; 347.1 H ₂ N-18; 244.0 N; 226.0 N-18	7.6%	6.0%	GlcNAc(β1-2)Man(α1-6)Man(β1-4) GlcNAc [15]
933.4 H ₃ N ₂ ; 915.3 H ₃ N ₂ -18; 771.5 H ₂ N ₂ ; 730.4 H ₃ N; 712.3 H ₃ N-18; 568.2 H ₂ N; 550.2 H ₂ N-18	0.6%	1.1%	GlcNAc(β1-2)Man(α1-6)[GlcNAc(β1-2) Man(α1-3)]Man(β1-4)GlcNAc [15,16,44]
933.4 H ₃ N ₂ ; 915.3 H ₃ N ₂ -18; 730.5 H ₃ N; 712.4 H ₃ N-18; 550.3 H ₂ N-18	3.6%	1.3%	
933.5 H ₃ N ₂ ; 915.3 H ₃ N ₂ -18; 730.5 H ₃ N; 712.3 H ₃ N-18; 568.3 H ₂ N; 550.2 H ₂ N-18; 347.1 H ₂ -18	3.8%	5.8%	
	0.4%		
1136.4 H ₃ N ₃ ; 1118.5 H ₃ N ₃ -18; 974.6 H ₂ N ₂ ; 933.3 H ₃ N ₂ ; 915.4 H ₃ N ₂ -18; 730.6 H ₃ N; 712.3 H ₃ N-18; 568.4 H ₂ N; 550.4 H ₂ N-18; 532.3 H ₂ N-2x18; 406.1 HN; 387.9 HN-18	5.5%		GlcNAc(β1-2)Man(α1-6)[GlcNAc(β1-2) [GlcNAc(β1-4)]Man(α1-3)]Man(β1-4) GlcNAc [44,44,60]
1136.4/579.8 H ₃ N ₃ ; 1118.5/570.9 H ₃ N ₃ -18; 974.3 H ₂ N ₂ ; 933.4/478.2 H ₃ N ₂ ; 915.3 H ₃ N ₂ -18; 897.4 H ₃ N ₂ -2x18; 771.3 H ₂ N ₂ ; 753.4 H ₂ N ₂ -18; 712.2 H ₃ N-18; 591.4 HN ₂ -18; 568.4 H ₂ N; 388.2 HN-18; 244.0 N; 226.0 N-18	7.1%	15.5%	GlcNAc(β1-2)[GlcNAc(β1-4)]Man(α1-6) [GlcNAc(β1-2)Man(α1-3)]Man(β1-4) GlcNAc [15]
1136.4/579.8 H ₃ N ₃ ; 1118.4/570.8 H ₃ N ₃ -18; 974.3 H ₂ N ₂ ; 933.3/478.2 H ₃ N ₂ ; 915.3/469.2 H ₃ N ₂ -18; 771.5 H ₂ N ₂ ; 730.4 H ₃ N; 591.3 HN ₂ -18; 489.7 H ₂ N ₃ -9; 388.1 HN-18; 364.8 H ₂ ; 347.1 H ₂ -18; 226.0 N-18	1.7%		
1136.4 H ₃ N ₃ ; 1118.5 H ₃ N ₃ -18; 974.3 H ₂ N ₂ ; 933.4 H ₃ N ₂ ; 915.3 H ₃ N ₂ -18; 897.4 H ₃ N ₂ -2x18; 771.3 H ₂ N ₂ ; 753.4 H ₂ N ₂ -18; 712.2 H ₃ N-18; 591.4 HN ₂ -18; 568.4 H ₂ N; 388.2 HN-18; 244.0 N; 226.0 N-18	0.1%		
771.4 H ₂ N ₂ ; 753.4 H ₂ N ₂ -18; 609.4 HN ₂ ; 568.3 H ₂ N; 550.3 H ₂ N-18; 365.0 H ₂ ; 347.1 H ₂ -18	1.3%	1.2%	GlcNAc(β1-2)Man(α1-3)[GlcNAc(β1-4)] Man(β1-4)GlcNAc [16,44]

Table S5-4. continued

	Comp.	Registered m/z	Charge state	Ret. time (min)
Other glycans	H ₂	365.2	[M+Na] ⁺	7.8
				9.4
				11.3
	HN	406.2	[M+Na] ⁺	8.8
	H ₃	527.3	[M+Na] ⁺	7.8
				11.1
				12.1
				14.2
				16.2
				18.7
				23.1
	H ₄	689.5	[M+Na] ⁺	22.7
				23.2
	HF	349.2	[M+Na] ⁺	8.8
	H ₂ F	511.3	[M+Na] ⁺	9.8
	NF	390.2	[M+Na] ⁺	8.3
	H ₂ N	568.4	[M+Na] ⁺	9.7
				11.9
	H ₃ N	730.4	[M+Na] ⁺	9.3
	H ₄ N	892.4	[M+Na] ⁺	9.8
	H ₅ N	1054.5	[M+Na] ⁺	11.0
	H ₂ NF	714.5	[M+Na] ⁺	9.4
	H ₂ NF ₂	860.4	[M+Na] ⁺	7.6
	HNF	552.5	[M+Na] ⁺	8.8
	H ₂ S	656.5	[M+Na] ⁺	23.8
		678.5	[M-H+2Na] ⁺	
	N ₂ S	738.4	[M+Na] ⁺	25.1
		760.3	[M-H+2Na] ⁺	
	HNS	719.4	[M-H+2Na] ⁺	23.5
	HNSF	865.4	[M-H+2Na] ⁺	22.3
		865.4	[M-H+2Na] ⁺	24.3
	HS	516.4	[M-H+2Na] ⁺	23.8
	HX	381.2	[M+Na] ⁺	20.4
		403.2	[M-H+2Na] ⁺	

Fragment ions	Relative Area		Proposed structure
	U3	U4	
203.0 H		0.3%	
203.0 H; 185.0 H-18	47.0%	30.3%	
203.0 H; 185.0 H-18		0.8%	
244.0 N; 226.0 N-18; 203.0 H; 185.2 H-18	3.6%	2.5%	
		0.2%	
365.1 H ₂ ; 347.0 H ₂ -18; 185.2 H-18	1.6%	0.8%	
365.0 H ₂ ; 347.0 H ₂ -18; 203.1 H; 184.9 H-18	0.7%	1.3%	
	0.8%	0.5%	
365.1 H ₂ ; 347.0 H ₂ -18; 203.0 H; 185.1 H-18	0.4%	1.4%	
365.1 H ₂ ; 203.0 H; 185.0 H-18	0.7%	0.7%	
365.1 H ₂ ; 347.0 H ₂ -18; 202.9 H; 185.0 H-18	2.0%	0.7%	
527.2 H ₃ ; 509.2 H ₃ -18; 365.0 H ₂ ; 347.0 H ₂ -18; 203.0 H	0.7%	0.3%	
527.2 H ₃ ; 509.3 H ₃ -18; 365.0 H ₂ ; 347.0 H ₂ -18	1.5%	0.4%	
203.0 H; 185.1 H-18; 169.1 F-18	0.7%	15.5%	
365.1 H ₂ ; 347.1 H ₂ -18; 330.8 HF-18	0.6%	0.7%	
	0.2%		
347.1 H ₂ -18	0.9%	1.7%	
	0.1%		
	0.4%	0.5%	
	0.3%	0.3%	
	0.2%		
568.4 H ₂ N; 552.4 HNF; 550.3 H ₂ N-18; 534.3 HNF-18; 406.2 HN; 389.9 NF; 388.1 HN-18; 372.1 NF-18; 365.1 H ₂ ; 244.1 N; 203.0 H	0.6%	0.8%	
	0.2%	0.1%	
406.1 HN; 388.1 HN-18; 226.0 N-18; 207.8 N-2x18; 203.0 H; 185.1 H-18	0.5%	0.2%	
498.2 HS-18; 364.8 H ₂ ; 336.0 S-18	2.3%	2.2%	
	0.1%	0.1%	
516.2 HS; 498.3 HS-18; 406.0 HN; 388.1 HN-18; 353.9 S; 336.0 S-18	1.6%	1.5%	NeuAc(α2-6)Gal(β1-4)GlcNAc [37,50]
	0.2%		
	0.1%		
353.7 S; 335.9 S-18	0.2%	0.4%	
240.9 X; 203.0 H		3.6%	Gal(β1-4)GluconA [26]

Table S5-5. Oligosaccharide species detected in the sialidosis samples. Comp., composition; Ret., retention; Rel. area., relative area.

	Comp.	Registered m/z	Charge state	Ret. time (min)
	HNS	697.6 719.5	$[M+Na]^+$ $[M-H+2Na]^+$	21.3
	H ₃ N ₂ S	1224.5 1246.8 624.1 635.1	$[M+Na]^+$ $[M-H+2Na]^+$ $[M+2Na]^{2+}$ $[M-H+3Na]^{2+}$	21.8
	H ₅ N ₃ S	887.6 898.3	$[M+2Na]^{2+}$ $[M-H+3Na]^{2+}$	23.7
Disease related glycans	H ₅ N ₃ S ₂	1033.1 1044.1 1055.1	$[M+2Na]^{2+}$ $[M-H+3Na]^{2+}$ $[M-2H+4Na]^{2+}$	29.1
	H ₆ N ₄ S ₂	1237.4	$[M-2H+4Na]^{2+}$	28.8
	H ₃ SO ₃ N ₂ S	1304.3 1348.2 664.0 674.5 685.8	$[M+Na]^+$ $[M-2H+3Na]^+$ $[M+2Na]^{2+}$ $[M-H+3Na]^{2+}$ $[M-2H+4Na]^{2+}$	21.8
	H ₅ SO ₃ N ₃ S	1854.3 1876.3 927.2 938.3 949.4	$[M-H+2Na]^+$ $[M-2H+3Na]^+$ $[M+2Na]^{2+}$ $[M-H+3Na]^{2+}$ $[M-2H+4Na]^{2+}$	22.0
	H ₅ SO ₃ N ₃ S ₂	2166.6 1083.8	$[M-2H+3Na]^+$ $[M-H+3Na]^{2+}$	33.8

Fragment ions	Rel. area	
	U8	Proposed structure
516.2 HS; 498.2 HS-18; 406.1 HN; 388.1 HN-18; 354.0 S; 336.1 S-18; 318.0 S-2x18; 226.0 N-18	2.7%	NeuAc(α 2-6)Gal(β 1-4)GlcNAc [37,50]
1043.4/533.3 H ₃ NS; 1025.4/524.3 H ₃ NS-18; 933.4/477.9 H ₃ N ₂ ; 915.4 H ₃ N ₂ -18; 881.5/452.3 H ₂ NS; 863.3/443.0 H ₂ NS-18; 771.4 H ₂ N ₂ ; 753.5 H ₂ N ₂ -18; 730.4 H ₃ N; 712.5 H ₃ N-18; 719.4 HNS; 701.4 HNS-18; 568.4 H ₂ N; 550.2 H ₂ N-18; 516.3 HS; 498.3 HS-18; 406.1 HN; 388.1 HN-18; 365.0 H ₂ ; 347.3 H ₂ -18; 354.0 S; 336.0 S-18; 243.9 N; 226.0 N-18; 208.0 N-2x18; 203.1 H; 185.0 H-18	18.7%	Neu5Ac(α 2-3)Gal(β 1-4)GlcNAc(β 1-2)Man(α 1-3)Man(β 1-4)GlcNAc [38-40]
1460.5 H ₅ N ₃ ; 1442.6 H ₅ N ₃ -18; 1408.6 H ₄ N ₂ S; 1390.3 H ₄ N ₂ S-18; 1257.6 H ₃ N ₂ ; 1095.5 H ₄ N ₂ ; 1077.6 H ₄ N ₂ -18; 1025.2 H ₃ NS-18; 915.4 H ₃ N ₂ -18; 892.2 H ₄ N; 881.3 H ₂ NS; 797.4 H ₄ N ₂ S-9; 796.9 H ₂ N ₂ S; 771.5 H ₂ N ₂ ; 694.5 H ₃ N-2x18; 640.5 H ₅ N ₂ ; 605.0 H ₄ NS-9; 568.2 H ₂ N; 541.0 H ₄ N ₂ -2x9; 388.2 HN-18; 336.1/314.0 S-18	3.2%	Neu5Ac(α 2-3/6)Gal(β 1-4)GlcNAc(β 1-2)Man(α 1-6)[Gal(β 1-4)GlcNAc(β 1-2)Man(α 1-3)]Man(β 1-4)GlcNAc [38,39]
1773.4/898.5 H ₅ N ₃ S; 1733.1/1755.3/889.4 H ₅ N ₃ S-18; 1571.4/797.5 H ₄ N ₃ S-18; 1570.5 H ₅ N ₂ S; 1460.2/741.9 H ₅ N ₃ ; 1408.4 H ₄ N ₂ S; 1368.8 H ₄ N ₂ S-18; 1095.5 H ₄ N ₂ ; 953.4 H ₅ N ₂ S; 915.5 H ₃ N ₂ -18; 892.1 H ₄ N; 701.2 HNS-18; 694.4 H ₃ N-2x18; 605.3 H ₄ NS-9; 596.1 H ₄ NS-2x9; 313.9 S	8.7%	Neu5Ac(α 2-3/6)Gal(β 1-4)GlcNAc(β 1-2)Man(α 1-6)[Neu5Ac(α 2-3/6)Gal(β 1-4)GlcNAc(β 1-2)Man(α 1-3)]Man(β 1-4)GlcNAc [38-40]
933.5 H ₃ (SO ₃)N ₂ ; 701.4 H(SO ₃)NS-18; 645.6/634.9 H ₃ N ₂ S; 634.5 H ₂ (SO ₃)N; 516.3 H(SO ₃)S; 196.0 HN	0.0%	
	2.4%	Neu5Ac(α 2-3)Gal(6SO ₃)(β 1-4)GlcNAc(β 1-2)Man(α 1-3/6)Man(β 1-4)GlcNAc [26]
	0.9%	Neu5Ac, SO ₃ (6){Gal(β 1-4)GlcNAc(β 1-2)Man(α 1-6)[Gal(β 1-4)GlcNAc(β 1-2)Man(α 1-3)]Man(β 1-4)GlcNAc [26]}
	1.0%	2xNeu5Ac, SO ₃ (6){Gal(β 1-4)GlcNAc(β 1-2)Man(α 1-6)[Gal(β 1-4)GlcNAc(β 1-2)Man(α 1-3)]Man(β 1-4)GlcNAc [26]}

Table S5-5. continued

Comp.	Registered m/z	Charge state	Ret. time (min)
H ₂	365.2	[M+Na] ⁺	6.2
			7.4
			8.7
			10.2
			13.5
HS	516.3	[M-H+2Na] ⁺	21.7
H ₃	527.3	[M+Na] ⁺	8.9
			13.5
			18.2
			20.8
			22.5
H ₄	689.5	[M+Na] ⁺	28.1
			19.4
			21.2
HN	406.2	[M+Na] ⁺	7.4
H ₂ N	568.5	[M+Na] ⁺	7.5
H ₃ N	730.6	[M+Na] ⁺	8.5
			12.1
Other glycans	H ₄ N	[M+Na] ⁺	10.3
	H ₂ N ₂	[M+Na] ⁺	9.9
	H ₃ N ₂	[M+Na] ⁺	11.1
		[M+2Na] ²⁺	
	933.5	[M+Na] ⁺	13.4
	478.4	[M+2Na] ²⁺	
H ₅ N ₃	742.0	[M+2Na] ²⁺	18.4
H ₂ S	656.5	[M+Na] ⁺	12.8
	678.5	[M-H+2Na] ⁺	
			21.8
HF	349.2	[M+Na] ⁺	5.9
H ₂ F	511.4	[M+Na] ⁺	7.0
NF	390.2	[M+Na] ⁺	6.5
HNF	552.5	[M+Na] ⁺	6.7
			7.0
H ₂ NF	714.5	[M+Na] ⁺	6.7

Fragment ions	Rel. area	Proposed structure
	U8	
203.0 H	1.5%	
203.0 H ₂ ; 185.1 H-18	18.9%	
202.9 H ₂ ; 185.1 H-18	3.5%	
203.0 H ₂ ; 185.0 H-18	2.4%	
203.0 H ₂ ; 185.1 H-18	0.3%	
	1.0%	
365.2 H ₂ ; 347.1 H ₂ -18; 203.1 H; 185.0 H-18	3.2%	
365.1 H ₂ ; 347.0 H ₂ -18; 203.1 H; 185.1 H-18	0.3%	
365.1 H ₂ ; 347.0 H ₂ -18; 203.1 H; 185.1 H-18	0.6%	
	0.6%	
365.1 H ₂ ; 347.1 H ₂ -18; 203.1 H; 185.0 H-18	0.9%	
	0.7%	
	0.0%	
527.3 H ₂ ; 509.3 H ₃ -18; 365.0 H ₂ ; 347.0 H ₂ -18; 203.0 H	2.8%	
244.0 N; 226.0 N-18; 203.0 H; 185.1 H-18	5.4%	
365 H ₂ ; 347.0 H ₂ -18; 244.2 N	1.1%	
568.4 H ₂ N; 550.2 H ₂ N-18; 527.4 H ₃ ; 509.3 H ₃ -18; 406.0 HN; 388.2 HN-18; 364.9 H ₂ ; 347.0 H ₂ -18	1.3%	
568.3 H ₂ N; 550.3 H ₂ N-18; 509.3 H ₃ -18; 406.1 HN; 388.1 HN-18; 365.1 H ₂ ; 347.2 H ₂ -18; 244.1 N; 226.0 N-18; 203.0 H		
730.4 H ₂ N; 689.4 H ₄ ; 671.2 H ₄ -18; 568.3 H ₂ N; 550.3 H ₂ N-18; 509.4 H ₃ -18; 406.0 HN; 347.1 H ₂ -18	1.4%	
388.1 HN-18	0.3%	
771.5 H ₂ N ₂ ; 753.5 H ₂ N ₂ -18; 730.5 H ₃ N; 712.4 H ₃ N-18; 609.4 HN ₂ ; 568.4 H ₂ N; 550.3 H ₂ N-18; 527.3 H ₂ ; 509.2 H ₃ -18; 406.2 HN; 388.2 HN-18; 365.1 H ₂ ; 347.2 H ₂ -18	2.1%	
771.4 H ₂ N ₂ ; 753.5 H ₂ N ₂ -18; 730.4 H ₃ N; 712.4 H ₃ N-18; 568.4 H ₂ N; 550.4 H ₂ N-18; 509.4.3 H ₃ -18; 406.1 HN; 388.2 HN-18; 365.1 H ₂ ; 347.1 H ₂ -18	4.4%	
1298.5 H ₄ N ₃ ; 1280.3/651.6 H ₄ N ₃ -18; 1257.4/640.2 H ₃ N ₂ ; 1239.4 H ₃ N ₂ -18; 1095.4 H ₄ N ₂ ; 1077.4/550.2 H ₄ N ₂ -18; 933.4 H ₃ N ₂ ; 694.4 H ₃ N-2x18; 568.4 H ₂ N; 550.2 H ₂ N-18; 509.0 H ₃ -18; 451.0 H ₃ N ₂ -3x9; 388.1 HN-18; 329.0 H ₂ -2x18; 226.0 N-18	0.3%	
	0.4%	
516.3 HS; 498.2 HS-18; 480.1 HS-2x18; 365.0 H ₂ ; 354.1/332.1 S; 336.0/313.9 S-18; 317.9/296.0 S-2x18	1.7%	
	1.7%	
365.1 H ₂ ; 349.1 HF; 347.1 H ₂ -18; 331.1 HF-18; 203.0 H; 185.0 H-18	2.8%	Fuc{Gal(β1-4)Glc [37,46,47]}
	0.3%	
406.1 HN; 388.2 HN-18; 349.1 HF; 243.9 N; 226.1 N-18; 203.0 H	0.0%	GalNAc(α1-3)[Fuc(α1-2)]Gal [37]
406.1 HN; 390.2 NF; 388.2 HN-18; 372.0 NF-18; 226.0 N-18; 203.0 H	1.2%	
568.3 H ₂ N; 552.1 HNF; 550.4 H ₂ N-18; 534.3 HNF-18; 406.1 HN; 388.2 HN-18; 372.1 NF-18; 226.1 N-18; 208.0 N-2x18; 203.0 H	1.1%	

REFERENCES

1. Cantz M & Ulrich-Bott B (1990) Disorders of glycoprotein degradation. *J Inherit Metab Dis* **13**, 523-537.
2. Lundblad A, Lundsten J, Nordén NE, Sjöblad S, Svensson S, Öckerman PA, & Gehlhoof M (1978) Urinary abnormalities in fucosidosis. *Eur J Biochem* **83**, 513-521.
3. Öckerman PA (1969) Diseases of glycoprotein storage. *Lancet* **1**, 734.
4. Öckerman PA, Autio S, & Norden NE (1973) Diagnosis of mannosidosis. *Lancet* **1**, 207-208.
5. Winchester B (2005) Lysosomal metabolism of glycoproteins. *Glycobiology* **15**, 1R-15R.
6. Cantz M, Gehler J, & Spranger J (1977) Mucopolipidosis I: increased sialic acid content and deficiency of an alpha-N-acetylneuraminidase in cultured fibroblasts. *Biochem Biophys Res Commun* **74**, 732-738.
7. van Pelt J, Kamerling JP, Bakker HD, & Vliegthart JF (1991) A comparative study of sialyloligosaccharides isolated from sialidosis and galactosialidosis urine. *J Inherit Metab Dis* **14**, 730-740.
8. Landing BH, Silverman FN, Chadwick DL, Lahey ME, Jacoby MD, & Raig JM (1964) Familial neurovisceral lipidoses. An analysis of eight cases of a syndrome previously reported as "Hurler-variant," "Pseudo-Hurler," and "Tay-Sachs disease with visceral involvement". *Am J Dis Child* **108**, 503-522.
9. Takahashi Y & Orii T (1989) Severity of GM1 gangliosidosis and urinary oligosaccharide excretion. *Clin Chim Acta* **179**, 153-162.
10. Rubin M, Karpatis G, Wolfe LS, Carpenter S, Klavins MH, & Mahuran DJ (1988) Adult onset motor neuropathy in the juvenile type of hexosaminidase A and B deficiency. *J Neurol Sci* **87**, 103-119.
11. Hoffman LM, Amsterdam D, Brooks SE, & Schneck L (1977) Glycosphingolipids in fetal Tay-Sachs disease brain and lung cultures. *J Neurochem* **29**, 551-559.
12. Mahuran DJ (1999) Biochemical consequences of mutations causing the GM2 gangliosidosis. *Biochim Biophys Acta* **1455**, 105-138.
13. Hou Y, Tse R, & Mahuran DJ (1996) Direct determination of the substrate specificity of the alpha-active site in heterodimeric beta-hexosaminidase A. *Biochemistry (Mosc)* **35**, 3963-3969.
14. Kolter T & Sandhoff K (2006) Sphingolipid metabolism diseases. *Biochim Biophys Acta* **1758**, 2057-2079.
15. Strecker G, Herlant-Peers MC, Fournet B, & Montreuil J (1977) Structure of seven oligosaccharides excreted in the urine of a patient with Sandhoff's disease (GM2 gangliosidosis-variant O). *Eur J Biochem* **81**, 165-171.
16. Warner TG, De Kremer RD, Applegarth D, & Mock AK (1986) Diagnosis and characterization of GM 2 gangliosidosis type II (Sandhoff disease) by analysis of the accumulating N-acetyl-glucosaminyl oligosaccharides with high performance liquid chromatography. *Clin Chim Acta* **154**, 151-164.
17. Sewell AC (1979) An improved thin-layer chromatographic method for urinary oligosaccharide screening. *Clin Chim Acta* **92**, 411-414.
18. Kin NM (1987) Comparison of the urinary glycoconjugates excreted by patients with type I and type II fucosidosis. *Clin Chem* **33**, 44-47.
19. Schindler D, Kanzaki T, & Desnick RJ (1990) A method for the rapid detection of urinary glycopeptides in alpha-N-acetylglucosaminidase deficiency and other lysosomal storage diseases. *Clin Chim Acta* **190**, 81-91.
20. An Y, Young SP, Hillman SL, Van Hove JL, Chen YT, & Millington DS (2000) Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease. *Anal Biochem* **287**, 136-143.
21. Neville DC, Dwek RA, & Butters TD (2009) Development of a single column method for the separation of lipid- and protein-derived oligosaccharides. *J Proteome Res* **8**, 681-687.
22. Warner TG, Turner MW, Toone JR, & Applegarth D (1986) Prenatal diagnosis of infantile GM2 gangliosidosis type II (Sandhoff disease) by detection of N-acetylglucosaminyl-oligosaccharides in amniotic fluid with high-performance liquid chromatography. *Prenat Diagn* **6**, 393-400.
23. Peelen GO, de Jong JG, & Wevers RA (1994) HPLC analysis of oligosaccharides in urine from oligosaccharidosis patients. *Clin Chem* **40**, 914-921.
24. Wührer M, Koeleman CA, Deelder AM, & Hokke CH (2004) Normal-phase nanoscale liquid chromatography-mass spectrometry of underivatized oligosaccharides at low-femtomole sensitivity. *Anal Chem* **76**, 833-838.
25. Bruggink C, Wührer M, Koeleman CA, Barreto V, Liu Y, Pohl C, Ingendoh A, Hokke CH, & Deelder AM (2005) Oligosaccharide analysis by capillary-scale high-pH anion-exchange chromatography with on-line ion-trap mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci* **829**, 136-143.
26. Bruggink C, Poorthuis BJ, Piraud M, Froissart R, Deelder AM, & Wührer M (2010) Glycan profiling of urine, amniotic fluid and ascitic fluid from galactosialidosis patients reveals novel oligosaccharides with reducing end hexose and aldohexonic acid residues. *FEBS J* **277**, 2970-2986.

27. Packer NH, Lawson MA, Jardine DR, & Redmond JW (1998) A general approach to desalting oligosaccharides released from glycoproteins. *Glycoconj J* **15**, 737-747.
28. Rocklin RD, Clarke AP, & Weitzhandler M (1998) Improved long-term reproducibility for pulsed amperometric detection of carbohydrates via a new quadruple-potential waveform. *Anal Chem* **70**, 1496-1501.
29. Yamashita K, Kochibe N, Ohkura T, Ueda I, & Kobata A (1985) Fractionation of L-fucose-containing oligosaccharides on immobilized Aleuria aurantia lectin. *J Biol Chem* **260**, 4688-4693.
30. Michalski JC & Klein A (1999) Glycoprotein lysosomal storage disorders: alpha- and beta-mannosidosis, fucosidosis and alpha-N-acetylgalactosaminidase deficiency. *Biochim Biophys Acta* **1455**, 69-84.
31. Strecker G, Fournet B, Bouquelet S, Montreuil J, Dhondt JL, & Farriaux JP (1976) Chemistry of urinary mannosides excreted in mannosidosis. *Biochimie* **58**, 579-586.
32. Yamashita K, Tachibana Y, Mihara K, Okada S, Yabuuchi H, & Kobata A (1980) Urinary oligosaccharides of mannosidosis. *J Biol Chem* **255**, 5126-5133.
33. Matsuura F, Nunez HA, Grabowski GA, & Sweeley CC (1981) Structural studies of urinary oligosaccharides from patients with mannosidosis. *Arch Biochem Biophys* **207**, 337-352.
34. Yamashita K, Ohkura T, Okada S, Yabuuchi H, & Kobata A (1981) Urinary oligosaccharides of GM1-gangliosidosis. Different excretion patterns of oligosaccharides in the urine of type 1 and type 2 subgroups. *J Biol Chem* **256**, 4789-4798.
35. Klein A, Lebreton A, Lemoine J, Perini JM, Roussel P, & Michalski JC (1998) Identification of urinary oligosaccharides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. *Clin Chem* **44**, 2422-2428.
36. Warner TG, Robertson AD, & O'Brien JS (1983) Diagnosis of GM1 gangliosidosis based on detection of urinary oligosaccharides with high performance liquid chromatography. *Clin Chim Acta* **127**, 313-326.
37. Lundblad A (1978) Oligosaccharides from human urine. In *Methods in Enzymology* (Ginsburg V, ed), pp. 226-235. Academic Press, New York.
38. Michalski JC (1996) Normal and pathological catabolism of glycoproteins: catabolic pathway. In *Glycoproteins and Disease* (Montreuil J, Vliegenthart JF & Schachter H, eds), pp. 55-88. Elsevier Science.
39. Lowden JA & O'Brien JS (1979) Sialidosis: a review of human neuraminidase deficiency. *Am J Hum Genet* **31**, 1-18.
40. van Pelt J, Kamerling JP, Vliegenthart JF, Hoogeveen AT, & Galjaard H (1988) A comparative study of the accumulated sialic acid-containing oligosaccharides from cultured human galactosialidosis and sialidosis fibroblasts. *Clin Chim Acta* **174**, 325-335.
41. Spina E, Sturiale L, Romeo D, Impallomeni G, Garozzo D, Waidelich D, & Glueckmann M (2004) New fragmentation mechanisms in matrix-assisted laser desorption/ionization time-of-flight/time-of-flight tandem mass spectrometry of carbohydrates. *Rapid Commun Mass Spectrom* **18**, 392-398.
42. Harvey DJ (2000) Electrospray mass spectrometry and fragmentation of N-linked carbohydrates derivatized at the reducing terminus. *J Am Soc Mass Spectrom* **11**, 900-915.
43. Weiskopf AS, Vouros P, & Harvey DJ (1998) Electrospray ionization-ion trap mass spectrometry for structural analysis of complex N-linked glycoprotein oligosaccharides. *Anal Chem* **70**, 4441-4447.
44. Ramsay SL, Meikle PJ, Hopwood JJ, & Clements PR (2005) Profiling oligosaccharidurias by electrospray tandem mass spectrometry: quantifying reducing oligosaccharides. *Anal Biochem* **345**, 30-46.
45. Jardine I, Matsuura F, & Sweeley CC (1984) Electron ionization mass spectra of reduced and permethylated urinary oligosaccharides from patients with mannosidosis. *Biomed Mass Spectrom* **11**, 562-568.
46. Kunz C, Rudloff S, Baier W, Klein N, & Strobel S (2000) Oligosaccharides in human milk: structural, functional, and metabolic aspects. *Annu Rev Nutr* **20**, 699-722.
47. Finke B, Stahl B, Pfenninger A, Karas M, Daniel H, & Sawatzki G (1999) Analysis of high-molecular-weight oligosaccharides from human milk by liquid chromatography and MALDI-MS. *Anal Chem* **71**, 3755-3762.
48. Pfenninger A, Karas M, Finke B, & Stahl B (2002) Structural analysis of underivatized neutral human milk oligosaccharides in the negative ion mode by nano-electrospray MS(n) (part 1: methodology). *J Am Soc Mass Spectrom* **13**, 1331-1340.
49. Naarding MA, Ludwig IS, Groot F, Berkhout B, Geijtenbeek TB, Pollakis G, & Paxton WA (2005) Lewis X component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. *J Clin Invest* **115**, 3256-3264.
50. Parkkinen J & Finne J (1983) Isolation and structural characterization of five major sialyloligosaccharides and a sialylglycopeptide from normal human urine. *Eur J Biochem* **136**, 355-361.
51. Koseki M & Tsurumi K (1977) A convenient method for the isolation of 3'-sialyllactose from normal human urine. *J Biochem* **82**, 1785-1788.

52. Hardy MR & Townsend RR (1988) Separation of positional isomers of oligosaccharides and glycopeptides by high-performance anion-exchange chromatography with pulsed amperometric detection. *Proc Natl Acad Sci U S A* **85**, 3289-3293.
53. Townsend RR, Hardy MR, Hindsgaul O, & Lee YC (1988) High-performance anion-exchange chromatography of oligosaccharides using pellicular resins and pulsed amperometric detection. *Anal Biochem* **174**, 459-470.
54. Townsend RR, Hardy MR, & Lee YC (1989) Separation of oligosaccharides using high-performance anion-exchange chromatography with pulsed amperometric detection. *Methods Enzymol* **179**, 65-76.
55. Vellodi A (2005) Lysosomal storage disorders. *Br J Haematol* **128**, 413-431.
56. Strecker G, Fournet B, & Montreuil J (1978) Structure of the three major fucosyl-glycoasparagines accumulating in the urine of a patient with fucosidosis. *Biochimie* **60**, 725-734.
57. Tsay GC & Dawson G (1976) Oligosaccharide storage in brains from patients with fucosidosis, GM1-gangliosidosis and GM2-gangliosidosis (Sandhoff's disease). *J Neurochem* **27**, 733-740.
58. Tsay GC, Dawson G, & Sung SS (1976) Structure of the accumulating oligosaccharide in fucosidosis. *J Biol Chem* **251**, 5852-5859.
59. Nishigaki M, Yamashita K, Matsuda J, Arashima S, & Kobata A (1978) Urinary oligosaccharides of fucosidosis. Evidence of the occurrence of X-antigenic determinant in serum-type sugar chains of glycoproteins. *J Biochem* **84**, 823-834.
60. Warner TG, deKremer RD, Mock AK, & Sjöberg ER (1985) Characterization and analysis of branched-chain *N*-acetylglucosaminyl oligosaccharides accumulating in Sandhoff disease tissue. Evidence that biantennary bisected oligosaccharide side chains of glycoproteins are abundant substrates for lysosomes. *J Biol Chem* **260**, 6194-6199.
61. Dorland L, Haverkamp J, Vliegenthart JF, Strecker G, Michalski JC, Fournet B, Spik G, & Montreuil J (1978) 360-MHz ¹H nuclear-magnetic-resonance spectroscopy of sialyl-oligosaccharides from patients with sialidosis (mucopolipidosis I and II). *Eur J Biochem* **87**, 323-329.
62. Charlwood J, Tolson D, & Camilleri P (1999) A detailed analysis of neutral and acidic carbohydrates in human milk. *Anal Biochem* **273**, 261-277.
63. Fong BY, Ma K, & McJarrow P (2011) Quantification of Bovine Milk Oligosaccharides Using Liquid Chromatography Selected Reaction Monitoring-Mass Spectrometry. *J Agric Food Chem* **59**, 9788-9795.
64. Anumula KR (2006) Advances in fluorescence derivatization methods for high-performance liquid chromatographic analysis of glycoprotein carbohydrates. *Anal Biochem* **350**, 1-23.
65. Ruhaak LR, Zauner G, Huhn C, Bruggink C, Deelder AM, & Wuhrer M (2010) Glycan labeling strategies and their use in identification and quantification. *Anal Bioanal Chem* **397**, 3457-3481.
66. Bruggink C, Maurer R, Herrmann H, Cavalli S, & Hoefler F (2005) Analysis of carbohydrates by anion exchange chromatography and mass spectrometry. *J Chromatogr A* **1085**, 104-109.
67. Rabin S, Stillian JR, Barreto V, Friedman K, & Toofan M (1993) New membrane-based electrolytic suppressor device for suppressed conductivity detection in ion chromatography. *J Chromatogr* **640**, 97-109.
68. Liu Y, Srinivasan K, Pohl C, & Avdalovic N (2004) Recent developments in electrolytic devices for ion chromatography. *J Biochem Biophys Methods* **60**, 205-232.

